BACKGROUND O
: O
Ischemic O
heart O
disease O
is O
the O
primary O
cause O
of O
morbidity O
and O
mortality O
among O
diabetics I-GENE
, O
especially O
those O
who O
became O
ill I-GENE
at O
a O
young O
age O
. O

More O
importantly I-GENE
, O
this O
fusion I-GENE
converted O
a O
less O
effective O
vaccine O
into O
one O
with O
significant O
potency O
against O
established O
E7 I-GENE
- I-GENE
expressing O
metastatic O
tumors O
. O

Reverse I-GENE
transcription I-GENE
- I-GENE
PCR O
analysis O
of O
mRNA I-GENE
from O
patients O
shows O
that O
each O
of O
these O
five O
mutations O
results O
in O
aberrant O
splicing O
. O

Using O
the O
postural I-GENE
and O
force O
data O
as O
input O
to O
a O
3 I-GENE
- I-GENE
D I-GENE
biomechanical I-GENE
model O
, O
the O
lumbosacral I-GENE
spinal O
compression O
was O
calculated O
. O

Sequence O
analysis O
revealed O
significant O
differences O
between O
the O
5 I-GENE
' O
region O
of O
the O
beta I-GENE
subunit I-GENE
gene I-GENE
and O
the O
corresponding O
regions O
of O
the O
homologous O
GlyR I-GENE
alpha I-GENE
subunit I-GENE
genes I-GENE
; O
it O
also O
identified O
a O
novel O
exon O
( O
exon O
0 O
) O
that O
encodes O
most O
of O
the O
5 I-GENE
'- O
untranslated O
portion O
of O
the O
GlyR I-GENE
beta I-GENE
mRNA I-GENE
. O

Therefore O
, O
we O
suggested O
that O
both O
proteins I-GENE
might O
belong O
to O
the O
PLTP I-GENE
family I-GENE
. O

Influence O
of O
compression O
therapy O
on O
symptoms O
following O
soft O
tissue I-GENE
injury O
from O
maximal O
eccentric I-GENE
exercise O
. O

STAT5A I-GENE
mutations O
in O
the O
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
and O
SH3 I-GENE
domains I-GENE
did O
not O
alter O
the O
BTK I-GENE
- I-GENE
mediated O
tyrosine I-GENE
phosphorylation O
. O

In O
the O
present O
work O
, O
the O
complete O
genome O
sequences I-GENE
of O
Pyrococcus I-GENE
horikoshii I-GENE
and O
Pyrococcus I-GENE
abyssi I-GENE
, O
two O
species O
in O
a O
genus O
of O
hyperthermophilic I-GENE
archaeon I-GENE
( O
archaebacterium I-GENE
), O
were O
compared O
to O
detect O
large O
genome O
polymorphisms I-GENE
linked O
with O
restriction I-GENE
- I-GENE
modification O
gene I-GENE
homologs I-GENE
. O

In O
addition O
, O
these O
patients O
show O
both O
quantitative O
and O
qualitative O
differences O
in O
their O
infectious O
microbiological I-GENE
spectrum O
, O
mainly O
in O
clean I-GENE
- I-GENE
contaminated O
, O
contaminated O
and O
dirty I-GENE
surgical O
procedures O
. O

Here O
we O
show O
that O
PKC I-GENE
and O
p44 I-GENE
/ I-GENE
p42MAPK I-GENE
signalings I-GENE
are O
required O
for O
the O
HBx I-GENE
- I-GENE
induced O
Sp1 I-GENE
- I-GENE
mediated O
IGF I-GENE
- I-GENE
II I-GENE
P4 I-GENE
transcriptional O
activity O
since O
( O
i O
) O
PKC I-GENE
activation O
by O
PMA O
or O
PKC I-GENE
expression O
vector O
increases O
Sp1 I-GENE
phosphorylation O
and O
P4 I-GENE
activity O
in O
HBx I-GENE
- I-GENE
transfected O
HepG2 O
cells O
; O
( O
ii O
) O
PKC I-GENE
inhibition O
by O
PKC I-GENE
inhibitor I-GENE
Go6976 I-GENE
reduces O
Sp1 I-GENE
phosphorylation O
, O
P4 I-GENE
activity O
, O
and O
IGF I-GENE
- I-GENE
II I-GENE
mRNA I-GENE
in O
HBx I-GENE
- I-GENE
transfected O
HepG2 O
cells O
; O
and O
( O
iii O
) O
the O
inhibition O
of O
MEK I-GENE
activation O
by O
U0126 I-GENE
reduces O
Sp1 I-GENE
phosphorylation O
, O
P4 I-GENE
activity O
and O
IGF I-GENE
- I-GENE
II I-GENE
mRNA I-GENE
in O
HBx I-GENE
- I-GENE
transfected O
HepG2 O
cells O
. O

We O
show O
that O
p73 I-GENE
can O
transcriptionally O
inhibit O
a O
number O
of O
cellular O
and O
viral I-GENE
promoters I-GENE
. O

Similarly O
, O
curcumin I-GENE
( O
diferuloylmethane I-GENE
), O
an O
anti I-GENE
- I-GENE
inflammatory O
agent O
, O
suppressed O
OSM I-GENE
- I-GENE
stimulated O
STAT1 I-GENE
phosphorylation O
, O
DNA I-GENE
- I-GENE
binding I-GENE
activity O
of O
STAT1 I-GENE
, O
and O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation O
without O
affecting O
JAK1 I-GENE
, O
JAK2 I-GENE
, O
JAK3 I-GENE
, O
ERK1 I-GENE
/ I-GENE
2 I-GENE
, O
and O
p38 I-GENE
phosphorylation O
. O

The O
effects O
of O
the O
transfected O
receptors I-GENE
were O
associated I-GENE
with O
antagonism I-GENE
of O
activator I-GENE
protein I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
activity O
. O

Furthermore O
, O
the O
soluble I-GENE
forms O
of O
ATF6 I-GENE
and O
the O
G13 I-GENE
gene I-GENE
product I-GENE
are O
unable O
to O
bind O
to O
several O
point O
mutants I-GENE
of O
the O
cis O
- I-GENE
acting O
ER I-GENE
stress O
response O
element I-GENE
in O
vitro O
that O
hardly I-GENE
respond O
to O
ER I-GENE
stress O
in O
vivo O
. O

PURPOSE O
: O
The O
objective O
of O
this O
study O
was O
to O
assess O
first O
embryo O
cleavage O
( O
FEC I-GENE
) O
25 O
- I-GENE
27 O
h O
after O
intracytoplasmic I-GENE
sperm O
injection O
( O
ICSI I-GENE
) O
as O
a O
parameter O
for O
the O
embryo O
selection O
process O
. O

RESULTS O
: O
A I-GENE
significant O
correlation O
( O
p O
< O
0 O
. O
001 O
) O
was O
observed O
for O
mean O
wall O
thickness O
and O
vessel O
wall O
area O
between O
MRI O
and O
histopathology I-GENE
( O
r O
= O
0 O
. O
87 O
and O
r O
= O
0 O
. O
85 O
, O
respectively O
). O

Molecular O
cloning O
, O
genomic O
mapping O
, O
and O
expression O
of O
two O
secretor I-GENE
blood O
group O
alpha I-GENE
( O
1 I-GENE
, O
2 I-GENE
) O
fucosyltransferase I-GENE
genes I-GENE
differentially O
regulated O
in O
mouse I-GENE
uterine O
epithelium O
and O
gastrointestinal O
tract O
. O

We O
show O
that O
several O
heme O
- I-GENE
responsive I-GENE
mechanisms O
combine I-GENE
to O
regulate O
DAN I-GENE
/ I-GENE
TIR I-GENE
gene I-GENE
expression O
. O

No O
' O
TATA I-GENE
' O
motif I-GENE
was O
identified O
near O
either O
the O
GABPalpha I-GENE
or O
ATPsynCF6 I-GENE
transcription I-GENE
start O
sites I-GENE
. O

These O
results O
indicate O
the O
presence O
of O
TATA I-GENE
- I-GENE
unified I-GENE
transcription I-GENE
systems O
in O
contemporary I-GENE
eukaryotes O
and O
provide O
insight O
into O
the O
residual O
need O
for O
TBP I-GENE
by O
all O
three O
Pols I-GENE
in O
other O
eukaryotes O
despite O
a O
lack O
of O
TATA I-GENE
elements O
in O
their O
promoters I-GENE
. O

Different I-GENE
thermoluminescent I-GENE
detectors I-GENE
( O
TLD I-GENE
) O
have O
been O
used O
to O
measure O
the O
contribution O
of O
the O
low O
linear O
energy O
transfer I-GENE
component O
( O
LET I-GENE
< O
10 O
keV I-GENE
/ I-GENE
micrometer I-GENE
) O
and O
plastic I-GENE
nuclear I-GENE
track I-GENE
detectors I-GENE
( O
PNTD I-GENE
) O
for O
the O
high O
linear O
energy O
tranfer I-GENE
( O
LET I-GENE
) O
component O
. O

However O
, O
the O
beta5L I-GENE
splice O
variant I-GENE
was O
found O
only O
in O
the O
retina O
. O

This O
analysis O
supports O
the O
use O
of O
fluticasone I-GENE
propionate I-GENE
88 O
microg O
twice O
daily O
as O
first O
- I-GENE
line O
treatment O
in O
patients O
with O
persistent O
asthma O
previously O
treated O
with O
short O
- I-GENE
acting O
beta2 I-GENE
- I-GENE
agonist O
alone O
. O

The O
mice O
are O
phenotypically I-GENE
normal O
and O
do O
not O
develop O
spontaneous O
tumors O
at O
an O
early I-GENE
age O
, O
in O
contrast O
to O
knock I-GENE
- I-GENE
out O
( O
p53 I-GENE
(-/-)) I-GENE
strains O
with O
a O
defective O
p53 I-GENE
gene I-GENE
. O

Furthermore O
, O
stable O
expression O
of O
a O
constitutively O
active O
form O
of O
chicken I-GENE
Notch1 I-GENE
or O
Notch2 I-GENE
in O
a O
B I-GENE
cell O
line O
results O
in O
a O
down O
- I-GENE
regulation O
of O
surface O
IgM I-GENE
expression O
, O
which O
is O
accompanied O
by O
the O
reduction O
of O
IgH I-GENE
gene I-GENE
transcripts I-GENE
. O

On O
Cox O
proportional I-GENE
hazards I-GENE
regression O
adenocarcinoma O
( O
P I-GENE
= O
0 O
. O
006 I-GENE
), O
the O
development O
of O
BPF I-GENE
( O
P I-GENE
= O
0 O
. O
003 I-GENE
), O
older O
age O
( O
P I-GENE
= O
0 O
. O
03 O
) O
and O
higher O
pathological O
stage O
( O
P I-GENE
= O
0 O
. O
02 O
) O
were O
independent O
adverse O
predictors O
of O
survival O
. O

We O
found O
that O
RhoA I-GENE
can O
initiate O
a O
linear O
kinase I-GENE
cascade O
leading O
to O
the O
activation O
of O
ERK6 I-GENE
( O
p38 I-GENE
gamma I-GENE
), O
a O
recently O
identified O
member O
of O
the O
p38 I-GENE
family I-GENE
of O
MAPKs I-GENE
. O

Twenty O
- I-GENE
six O
( O
55 O
%) O
( O
95 O
% O
CI O
, O
41 O
- I-GENE
69 O
%) O
patients O
experienced O
> O
or O
= O
grade O
3 I-GENE
acute O
toxicity O
( O
RTOG I-GENE
). O

We O
hypothesize I-GENE
that O
proprioception I-GENE
may O
be O
used O
to O
calibrate I-GENE
the O
efference I-GENE
copy O
during O
development O
and O
in O
response O
to O
perturbations I-GENE
by O
signaling O
potential O
mismatches I-GENE
between O
eye O
movement O
information O
derived O
from O
the O
efferent I-GENE
command I-GENE
and O
the O
actual O
motion O
of O
the O
eye O
transduced I-GENE
by O
the O
proprioceptive I-GENE
organs O
. O

Thus O
, O
BALB O
/ I-GENE
c I-GENE
mice O
appear O
to O
be O
the O
most O
appropriate O
strain O
of O
mice O
to O
perform O
studies O
on O
the O
possible O
connection I-GENE
between O
infection O
with O
T I-GENE
. O
canis I-GENE
and O
allergic O
asthma O
. O

They O
correspond O
to O
nucleotides O
equivalent O
to O
base O
- I-GENE
pair O
C1 I-GENE
- I-GENE
G72 I-GENE
and O
discriminator I-GENE
base O
A73 I-GENE
in O
the O
amino O
acid I-GENE
- I-GENE
acceptor O
branch O
of O
the O
molecule I-GENE
. O

Our O
results O
suggest O
that O
the O
central O
role O
of O
the O
Notch I-GENE
- I-GENE
CBF1 I-GENE
/ I-GENE
RBP I-GENE
- I-GENE
Jkappa I-GENE
signaling O
pathway O
in O
cell O
fate O
decisions I-GENE
renders I-GENE
it O
susceptible O
to O
pathways O
of O
viral I-GENE
replication O
and O
oncogenic I-GENE
conversion O
. O

High O
- I-GENE
affinity O
binding I-GENE
of O
NF I-GENE
- I-GENE
1 I-GENE
to O
PSE I-GENE
- I-GENE
B I-GENE
, O
but O
not O
to O
PSE I-GENE
- I-GENE
A I-GENE
, O
was O
confirmed O
by O
competition O
of O
DNA I-GENE
- I-GENE
protein I-GENE
interactions O
by O
using O
NF I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
elements O
and O
antibodies I-GENE
. O

The O
first O
case O
of O
HCV I-GENE
seroconversion I-GENE
in O
Portugal I-GENE
after O
the O
introduction O
of O
HCV I-GENE
NAT I-GENE
screening O
. O

Substitutions I-GENE
in O
the O
YFV I-GENE
Ag I-GENE
- I-GENE
binding I-GENE
region O
( O
ABR I-GENE
) O
occur O
at O
four O
of O
the O
eight O
highly O
conserved O
residues O
that O
are O
essential O
for O
binding I-GENE
of O
peptide I-GENE
- I-GENE
Ag I-GENE
in O
the O
class I-GENE
Ia I-GENE
molecules I-GENE
. O

The O
Novacor I-GENE
Left I-GENE
Ventricular I-GENE
Assist I-GENE
System I-GENE
( O
LVAS I-GENE
) O
( O
Novacor I-GENE
Corp I-GENE
, O
Oakland I-GENE
, O
CA I-GENE
) O
was O
initially O
console I-GENE
- I-GENE
based O
and O
has O
been O
available O
since O
1993 O
in O
a O
wearable I-GENE
configuration O
. O

Ileal I-GENE
digestibilities I-GENE
of O
DM O
, O
OM I-GENE
, O
CP I-GENE
, O
total O
dietary O
fiber O
( O
TDF I-GENE
), O
fat O
and O
gross O
energy O
( O
GE I-GENE
) O
were O
lower O
( O
P I-GENE
< O
0 O
. O
05 O
) O
for O
dogs O
fed O
diets O
containing O
supplemental I-GENE
fiber O
compared O
with O
dogs O
fed O
the O
control O
diet O
. O

In O
addition O
, O
the O
consensus I-GENE
amino O
acid I-GENE
motif I-GENE
for O
serine I-GENE
threonine I-GENE
receptor I-GENE
kinases I-GENE
was O
also O
present O
. O

Here O
, O
we O
show O
that O
the O
phorbol O
ester O
PMA O
decreases O
both O
basal O
and O
dexamethasone O
/ I-GENE
cAMP I-GENE
- I-GENE
induced O
expression O
of O
a O
luciferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
G6Pase I-GENE
promoter I-GENE
in O
transiently O
transfected O
H4IIE I-GENE
hepatoma O
cells O
. O

The O
difference O
between O
the O
patients O
and O
the O
controls O
was O
statistically O
significant O
( O
p O
= O
0 O
. O
03 O
). O

Altogether O
, O
we O
confirm O
that O
all O
genes I-GENE
of O
the O
Rad52 I-GENE
recombinational I-GENE
repair I-GENE
pathway O
are O
required O
for O
the O
survival O
of O
rad27 I-GENE
Delta I-GENE
strains O
at O
both O
permissive O
( O
23 O
degrees O
C I-GENE
) O
and O
semipermissive I-GENE
( O
30 O
degrees O
C I-GENE
) O
temperatures O
for O
growth I-GENE
. O

Neuron I-GENE
- I-GENE
specific I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
homology I-GENE
3 I-GENE
domain I-GENE
- I-GENE
only O
splice O
variant I-GENE
of O
Bak I-GENE
is O
anti I-GENE
- I-GENE
apoptotic O
in O
neurons O
, O
but O
pro I-GENE
- I-GENE
apoptotic O
in O
non O
- I-GENE
neuronal O
cells O
. O

The O
mechanism O
of O
the O
induction O
of O
3beta I-GENE
- I-GENE
HSD I-GENE
type I-GENE
1 I-GENE
gene I-GENE
expression O
was O
further O
characterized O
in O
ZR I-GENE
- I-GENE
75 O
- I-GENE
1 I-GENE
human I-GENE
breast O
cancer O
cells O
. O

Contagious I-GENE
bovine I-GENE
pleuropneumonia I-GENE
is O
a O
major I-GENE
threat I-GENE
for O
cattle O
in O
Africa I-GENE
. O

Treatment O
includes O
both O
medical O
and O
surgical O
options I-GENE
, O
with O
medical O
therapy O
further O
subclassified I-GENE
into O
pharmacologic I-GENE
and O
pneumatic I-GENE
dilation I-GENE
. O

Since O
the O
latter O
is O
very O
small I-GENE
for O
physiological O
flows I-GENE
, O
the O
result O
is O
that O
alpha I-GENE
< O
1 I-GENE
even O
at O
relatively O
high O
values O
of O
the O
Reynolds I-GENE
number O
( O
i O
. O
e O
., O
for O
non O
- I-GENE
negligible I-GENE
inertia I-GENE
) O
and O
we O
validate I-GENE
our O
perturbation I-GENE
theory O
results O
by O
comparison O
with O
a O
numerical I-GENE
integration O
of O
the O
full I-GENE
model O
. O

This O
plus O
the O
reduced O
phosphorylation O
of O
p27 I-GENE
by O
MAPK I-GENE
enhanced O
the O
stability O
of O
p27 I-GENE
that O
associated I-GENE
with O
nuclear I-GENE
Cdk2 I-GENE
at O
high O
stoichiometry I-GENE
and O
inhibited O
its O
kinase I-GENE
activity O
. O

Similar O
data O
were O
also O
obtained O
when O
either O
dominant I-GENE
negative O
EGFR I-GENE
- I-GENE
CD533 I-GENE
or O
dominant I-GENE
negative O
Ras I-GENE
N17 I-GENE
were O
used O
to O
block O
MAPK I-GENE
activation O
. O

The O
assay O
herein I-GENE
described O
allows O
the O
comparison O
of O
relative O
FGFR I-GENE
expression O
levels O
, O
both O
within O
a O
single O
RNA I-GENE
pool O
and O
among O
multiple O
RNA I-GENE
pool O
samples O
. O

This O
was O
most O
pronounced O
during O
the O
initial O
phase O
of O
Erk I-GENE
activation O
. O

DESIGN O
: O
Prospective I-GENE
cohort O
study O
with O
a O
20 O
y I-GENE
follow O
- I-GENE
up O
period O
, O
the O
First O
National O
Health O
and O
Examination O
Survey I-GENE
( O
NHANES I-GENE
1 I-GENE
) O
Epidemiologic I-GENE
Follow I-GENE
- I-GENE
up O
Study O
( O
NHEFS I-GENE
). O

To O
assess O
the O
maximum O
oxygen O
uptake O
( O
V I-GENE
' O
O2 O
max O
) O
of O
Hong I-GENE
Kong I-GENE
Chinese O
children O
and O
to O
explore O
its O
association O
with O
respiratory O
illnesses I-GENE
, O
we O
conducted O
the O
Multistage I-GENE
Fitness I-GENE
Test O
( O
MFT I-GENE
), O
a O
20 O
- I-GENE
m I-GENE
shuttle I-GENE
run O
test O
, O
in O
1 I-GENE
, O
427 I-GENE
schoolchildren I-GENE
aged O
between O
8 O
- I-GENE
12 O
years O
. O

After O
all O
doses O
of O
d O
- I-GENE
amphetamine O
, O
responding O
occurred O
largely O
on O
the O
saline O
key O
under O
both O
schedules I-GENE
. O

A I-GENE
novel O
myeloid O
- I-GENE
restricted O
zebrafish I-GENE
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with O
a O
potent O
transcriptional O
activation O
domain I-GENE
. O

METHODS O
: O
Humphrey I-GENE
Field I-GENE
Analyzer I-GENE
model O
630 I-GENE
( O
HFA I-GENE
I I-GENE
, O
program O
30 O
- I-GENE
2 I-GENE
with O
a O
rectangular I-GENE
6 I-GENE
degrees O
x O
6 I-GENE
degrees O
grid I-GENE
) O
was O
used O
as O
the O
conventional O
perimetric I-GENE
method O
. O

These O
data O
reveal O
a O
complex I-GENE
network O
of O
interactions O
between O
GTPases I-GENE
in O
the O
ARF I-GENE
family I-GENE
and O
their O
effectors I-GENE
and O
reveal O
a O
potential O
for O
cross O
- I-GENE
talk I-GENE
not O
demonstrated O
previously O
. O

Net I-GENE
lift I-GENE
and O
combined O
drag I-GENE
from O
all O
8 O
bearings I-GENE
of O
the O
4 I-GENE
- I-GENE
bladed I-GENE
impeller I-GENE
are O
compared O
with O
predictions O
based O
on O
2 I-GENE
- I-GENE
D I-GENE
theory O
. O

In O
the O
course O
of O
screening O
for O
transcription I-GENE
factors I-GENE
which O
interact O
with O
the O
human I-GENE
myeloperoxidase I-GENE
( O
MPO I-GENE
) O
promoter I-GENE
we O
, O
for O
the O
first O
time O
, O
identified O
and O
cloned O
the O
cDNA I-GENE
and O
genomic O
DNA I-GENE
for O
human I-GENE
HBP1 I-GENE
( O
HMG I-GENE
- I-GENE
Box I-GENE
containing O
protein I-GENE
1 I-GENE
), O
a O
member O
of O
the O
high O
mobility I-GENE
group O
of O
non O
- I-GENE
histone I-GENE
chromosomal I-GENE
proteins I-GENE
. O

Therefore O
, O
vitamin O
D3 I-GENE
analogues O
have O
a O
substantial O
antipsoriatic I-GENE
effect O
. O

Methylation I-GENE
at O
both O
cytosine O
residues O
in O
the O
E2F I-GENE
element I-GENE
(( I-GENE
m I-GENE
) O
CG I-GENE
( O
m I-GENE
) O
CG I-GENE
) O
generated O
a O
new O
methylcytosine I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
. O

Hepatitis I-GENE
A I-GENE
infected O
food O
handler I-GENE
at O
an O
Edmonton I-GENE
, O
Alberta I-GENE
retail I-GENE
food O
facility I-GENE
: O
public I-GENE
health O
protection O
strategies O
. O

The O
co O
- I-GENE
existence O
of O
TE I-GENE
domains I-GENE
within O
modular I-GENE
PKSs I-GENE
along O
with O
physically O
separated O
, O
monofunctional I-GENE
TEs I-GENE
( O
TE I-GENE
IIs I-GENE
) O
has O
been O
reported O
for O
a O
number O
of O
modular I-GENE
polyketide I-GENE
and O
non O
- I-GENE
ribosomal I-GENE
peptide I-GENE
synthases I-GENE
( O
NRPS I-GENE
). O

Two O
independent O
transgenic O
lines O
were O
produced O
, O
and O
both O
showed O
expression O
of O
the O
Gus I-GENE
gene I-GENE
specifically O
in O
the O
endosperm I-GENE
during O
mid O
- I-GENE
development O
( O
first O
detected O
10 O
- I-GENE
12 O
d O
after O
anthesis I-GENE
). O

Treadmill I-GENE
training O
at O
least O
for O
2 I-GENE
weeks O
can O
reduce O
the O
infarction O
size O
and O
edema O
caused O
by O
MCA I-GENE
occlusion O
( O
P I-GENE
< O
0 O
. O
01 O
). O

Mechanism O
in O
the O
sequential O
control O
of O
cell O
morphology O
and O
S I-GENE
phase O
entry O
by O
epidermal I-GENE
growth I-GENE
factor I-GENE
involves O
distinct O
MEK I-GENE
/ I-GENE
ERK I-GENE
activations I-GENE
. O

We O
randomly O
assigned O
1 I-GENE
, O
219 I-GENE
subjects O
to O
receive O
either O
the O
standard O
three O
- I-GENE
times O
- I-GENE
weekly O
( O
TIW I-GENE
) O
interferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
dose O
( O
3 I-GENE
MIU I-GENE
) O
or O
the O
once O
- I-GENE
weekly O
( O
QW I-GENE
) O
peginterferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
( O
0 O
. O
5 I-GENE
, O
1 I-GENE
. O
0 O
, O
or O
1 I-GENE
. O
5 I-GENE
microg O
/ I-GENE
kg O
). O

These O
data O
suggest O
that O
proper O
direct O
binding I-GENE
of O
Nhp2p I-GENE
to O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNAs I-GENE
is O
required O
for O
the O
assembly O
of O
H I-GENE
/ I-GENE
ACA I-GENE
snoRNPs I-GENE
and O
hence O
for O
the O
stability O
of O
some O
of O
their O
components O
. O

The O
decrements I-GENE
in O
cerebrovascular I-GENE
resistance O
induced O
by O
hexamethonium I-GENE
, O
in O
mm O
Hg O
ml O
(- O
1 I-GENE
). O
min O
(- O
1 I-GENE
), O
were O
: O
under O
control O
. O

Here O
we O
provide O
the O
first O
evidence O
for O
the O
involvement O
of O
GCN1 I-GENE
- I-GENE
GCN2 I-GENE
interaction O
in O
activation O
of O
GCN2 I-GENE
per O
se I-GENE
. O

As O
a O
reflection I-GENE
of O
uncertainties I-GENE
in O
the O
estimates O
for O
individual O
sources O
, O
the O
90th I-GENE
percentiles I-GENE
of O
PCDD I-GENE
/ I-GENE
F I-GENE
releases I-GENE
for O
1999 I-GENE
ranged O
up O
to O
4 I-GENE
. O
1 I-GENE
g O
I I-GENE
- I-GENE
TEQ I-GENE
/ I-GENE
y I-GENE
. O

To O
test O
the O
hypothesis O
that O
these O
elements O
are O
required O
for O
promoter I-GENE
activity O
, O
we O
compared O
the O
reporter I-GENE
expression O
activity O
of O
segments O
containing O
mutations O
of O
these O
elements O
with O
activity O
of O
the O
parent I-GENE
Hlx I-GENE
promoter I-GENE
sequence I-GENE
. O

Using O
RACE O
techniques O
we O
have O
cloned O
and O
sequenced O
one O
of O
the O
hamster I-GENE
liver O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
hexobarbital I-GENE
dehydrogenases I-GENE
which O
catalyze I-GENE
not O
only O
cyclic I-GENE
alcohols I-GENE
but O
also O
17beta I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
steroids O
and O
3alpha I-GENE
- I-GENE
hydroxysteroids I-GENE
. O

Concerted I-GENE
transcriptional O
activation O
of O
the O
low O
density I-GENE
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
by O
insulin I-GENE
and O
luteinizing I-GENE
hormone I-GENE
in O
cultured O
porcine I-GENE
granulosa I-GENE
- I-GENE
luteal O
cells O
: O
possible O
convergence I-GENE
of O
protein I-GENE
kinase I-GENE
a O
, O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
and O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
pathways O
. O

Human I-GENE
T I-GENE
- I-GENE
cell O
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
( O
HTLV I-GENE
- I-GENE
I I-GENE
) O
Tax I-GENE
is O
a O
potent O
transcriptional O
regulator I-GENE
that O
can O
activate O
or O
repress O
specific I-GENE
cellular O
genes I-GENE
and O
that O
has O
been O
proposed O
to O
contribute O
to O
leukemogenesis I-GENE
in O
adult O
T I-GENE
- I-GENE
cell O
leukemia I-GENE
. O

Also O
, O
small I-GENE
, O
sense O
and O
antisense I-GENE
approximately O
22 O
nt O
RNAs I-GENE
, O
derived O
from O
the O
satRNA I-GENE
, O
were O
associated I-GENE
with O
the O
replicating I-GENE
satellite I-GENE
. O

Deletional I-GENE
analyses O
of O
VDR I-GENE
indicated O
that O
GRIP1 I-GENE
and O
RAC3 I-GENE
required O
an O
intact O
VDR I-GENE
activation O
function O
( O
AF I-GENE
- I-GENE
2 I-GENE
) O
domain I-GENE
for O
efficient O
interaction O
as O
well O
as O
additional O
but O
distinct O
regions O
of O
the O
VDR I-GENE
. O

RESULTS O
: O
During O
the O
stabilization O
period O
, O
PaCO2 O
( O
mean O
+/- O
SD O
) O
was O
33 O
+/- O
5 I-GENE
mm O
Hg O
, O
and O
arrhythmias O
were O
not O
detected O
. O

TT I-GENE
cells O
, O
a O
human I-GENE
MTC I-GENE
cell O
line O
expressing O
MEN I-GENE
2A I-GENE
type I-GENE
RET I-GENE
, O
display O
transcriptionally O
active O
RelA I-GENE
( O
p65 I-GENE
) O
in O
the O
nucleus O
. O

The O
human I-GENE
protein I-GENE
sequence I-GENE
exhibits O
a O
putative O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
similar O
to O
that O
seen O
in O
rat I-GENE
HBP1 I-GENE
and O
shows O
homology I-GENE
with O
the O
activation O
and O
repressor I-GENE
domains I-GENE
previously O
demonstrated O
in O
the O
rat I-GENE
protein I-GENE
. O

In O
contrast O
the O
human I-GENE
and O
mouse I-GENE
BCNT I-GENE
proteins I-GENE
contain O
one O
repeat I-GENE
unit I-GENE
and O
lack O
the O
RTE I-GENE
- I-GENE
1 I-GENE
- I-GENE
derived O
portion O
. O

Direct I-GENE
superoxide I-GENE
scavenging I-GENE
activity O
of O
nonsteroidal I-GENE
anti I-GENE
- I-GENE
inflammatory O
drugs O
: O
determination O
by O
electron O
spin O
resonance O
using O
the O
spin O
trap I-GENE
method O
. O

A I-GENE
single O
nucleotide I-GENE
polymorphism O
( O
SNP I-GENE
) O
in O
exon O
2 I-GENE
, O
which O
is O
tightly O
liked I-GENE
to O
another O
SNP I-GENE
( O
GTG83 I-GENE
/ I-GENE
ATG83 I-GENE
), O
creates I-GENE
an O
additional O
alternative O
in O
- I-GENE
frame O
AUG O
in O
B I-GENE
- I-GENE
type I-GENE
MTH1 I-GENE
mRNAs I-GENE
yielding I-GENE
the O
fourth O
MTH1 I-GENE
polypeptide I-GENE
, O
p26 I-GENE
that O
possesses O
an O
additional O
mitochondrial I-GENE
targeting O
signal I-GENE
. O

Six O
of O
the O
gstC I-GENE
' O
mutants I-GENE
, O
primarily O
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
half O
of O
C I-GENE
', O
exhibited O
a O
defect O
in O
the O
ability O
to O
bind O
L I-GENE
protein I-GENE
. O

We O
developed O
a O
system O
for O
domain I-GENE
shuffling I-GENE
to O
establish O
the O
function O
of O
C1 I-GENE
domains I-GENE
from O
human I-GENE
Raf I-GENE
kinase I-GENE
and O
rat I-GENE
PKC I-GENE
eta I-GENE
in O
yeast I-GENE
. O

Expression O
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
2 I-GENE
US3 I-GENE
affects O
the O
Cdc42 I-GENE
/ I-GENE
Rac I-GENE
pathway O
and O
attenuates O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation O
. O

Inhibition O
of O
constitutive O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
results O
in O
cell O
death O
of O
TT I-GENE
cells O
and O
blocks O
focus O
formation O
induced O
by O
oncogenic I-GENE
forms O
of O
RET I-GENE
in O
NIH O
3T3 O
cells O
. O

Corneal I-GENE
scrapping I-GENE
and O
deep O
stromal I-GENE
biopsy O
were O
obtained O
and O
stained O
for O
microscopic O
evaluation O
with O
periodic I-GENE
acid I-GENE
- I-GENE
Schiff I-GENE
, O
Giemsa I-GENE
, O
and O
Gomori I-GENE
' O
s O
methenamine I-GENE
silver O
stains I-GENE
. O

ICAM I-GENE
- I-GENE
1 I-GENE
has O
been O
suggested O
a O
predictor O
of O
the O
onset O
of O
GO I-GENE
. O

Once O
ICP I-GENE
reaches I-GENE
critical O
values O
(> O
30 O
mm O
Hg O
) O
herniation I-GENE
occurs O
, O
usually O
within O
2 I-GENE
to O
5 I-GENE
days O
. O

The O
present O
data O
also O
demonstrate O
that O
ectopic O
expression O
of O
blr1 I-GENE
increased O
JNK I-GENE
/ I-GENE
SAPK I-GENE
activity O
, O
but O
JNK I-GENE
/ I-GENE
SAPK I-GENE
activation O
was O
not O
needed O
for O
accelerated O
RA O
- I-GENE
induced O
differentiation O
and O
growth I-GENE
arrest O
. O

Here O
, O
we O
identify O
Rsc3 I-GENE
and O
Rsc30 I-GENE
as O
novel O
components O
of O
the O
essential O
yeast I-GENE
remodeler I-GENE
RSC I-GENE
complex I-GENE
. O

The O
pharmacokinetic O
profiles O
of O
digoxin I-GENE
and O
warfarin I-GENE
were O
not O
altered O
by O
the O
simultaneous O
and O
continued O
administration O
of O
sevelamer I-GENE
. O

Forskolin I-GENE
treatment O
( O
10 O
microM O
) O
of O
the O
transfected O
cells O
for O
3 I-GENE
-- O
6 I-GENE
h O
maximally I-GENE
induced O
luciferase I-GENE
threefold O
. O

E2F1 I-GENE
- I-GENE
mediated O
transcriptional O
inhibition O
of O
the O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
type I-GENE
1 I-GENE
gene I-GENE
. O

In O
this O
report O
this O
technique O
was O
applied O
to O
human I-GENE
breast O
carcinoma O
MDA I-GENE
- I-GENE
MB231 I-GENE
cells O
overexpressing O
human I-GENE
MPG I-GENE
in O
order O
to O
assess O
whether O
up O
- I-GENE
regulation O
of O
the O
initial O
step O
in O
BER I-GENE
alters O
the O
activity O
of O
selected O
other O
BER I-GENE
( O
hOGG1 I-GENE
and O
APE I-GENE
/ I-GENE
ref I-GENE
- I-GENE
1 I-GENE
) O
or O
direct O
reversal O
( O
MGMT I-GENE
) O
repair I-GENE
activities O
. O

Chlamydia O
and O
cervical O
cancer O
: O
a O
real O
association O
? O

In O
children O
unable O
to O
perform O
forced I-GENE
expiratory O
maneuvers I-GENE
( O
n O
= O
25 O
), O
FOT I-GENE
, O
contrary I-GENE
to O
the O
interrupter I-GENE
technique O
, O
clearly O
identified O
a O
subgroup O
of O
young O
children O
with O
high O
resistance O
values O
at O
baseline O
, O
which O
returned O
to O
normal O
after O
bronchodilation I-GENE
. O

Together O
, O
these O
results O
identify O
HPK1 I-GENE
as O
a O
new O
component O
of O
TCR I-GENE
signaling O
. O

Pro I-GENE
- I-GENE
inflammatory O
cytokine O
, O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
), O
produced O
from O
adipose I-GENE
tissues O
in O
obese O
subjects O
, O
is O
known O
to O
play O
a O
predominant O
role O
in O
inducing O
insulin I-GENE
resistance O
. O

The O
Schistosoma I-GENE
mansoni I-GENE
homologue I-GENE
( O
SmSmad2 I-GENE
) O
was O
overexpressed O
in O
bacteria O
as O
a O
Sj26 I-GENE
- I-GENE
GST I-GENE
fusion I-GENE
protein I-GENE
and O
used O
to O
raise I-GENE
specific I-GENE
antibodies I-GENE
. O

To O
study O
the O
in O
vivo O
role O
of O
p16 I-GENE
. O
7 O
, O
a O
phi29 I-GENE
mutant I-GENE
containing O
a O
suppressible I-GENE
mutation I-GENE
in O
gene I-GENE
16 O
. O
7 O
was O
constructed O
. O

The O
differences O
in O
the O
CPIgG I-GENE
, O
CRP I-GENE
, O
and O
fibrinogen I-GENE
levels O
in O
patients O
who O
were O
diagnosed O
with O
ACS I-GENE
versus O
those O
who O
were O
not O
( O
non O
- I-GENE
ACS I-GENE
) O
were O
evaluated O
. O

There O
are O
many O
different O
proposals I-GENE
for O
the O
statistical O
analysis O
of O
data O
to O
determine O
early I-GENE
onset O
of O
action O
. O

Coexpression I-GENE
of O
the O
p120 I-GENE
( O
ctn I-GENE
) O
protein I-GENE
with O
an O
N I-GENE
- I-GENE
terminal I-GENE
deletion O
, O
which O
eliminates I-GENE
some O
potential O
tyrosine I-GENE
phosphorylation O
sites I-GENE
, O
or O
the O
protein I-GENE
with O
a O
single O
amino O
acid I-GENE
substitution O
( O
tyrosine I-GENE
at O
217 I-GENE
to O
phenylalanine I-GENE
) O
resulted O
in O
an O
increase O
in O
the O
aggregation O
of O
v I-GENE
- I-GENE
Src I-GENE
- I-GENE
transformed O
EL I-GENE
and O
EalphaCL I-GENE
cells O
. O

We O
find O
that O
our O
response O
function O
is O
well O
approximated I-GENE
by O
the O
GSER I-GENE
only O
within O
a O
particular O
frequency O
range O
determined O
by O
the O
material O
parameters O
of O
both O
the O
bead I-GENE
and O
the O
network O
. O

The O
novel O
approach O
to O
insulin I-GENE
administration O
known O
as O
chronic O
intermittent O
intravenous O
insulin I-GENE
therapy O
( O
CIIIT I-GENE
) O
delivers I-GENE
insulin I-GENE
in O
a O
pulsatile I-GENE
fashion O
and O
achieves I-GENE
physiological O
insulin I-GENE
concentration O
in O
the O
portal I-GENE
vein O
. O

This O
article O
comparatively I-GENE
evaluates I-GENE
five O
Generic I-GENE
Systems I-GENE
that O
describe O
the O
basic I-GENE
alternatives I-GENE
to O
composting I-GENE
facility I-GENE
design O
and O
control O
. O

With O
a O
GC I-GENE
content O
of O
45 O
% O
the O
one O
segment O
would O
correspond O
to O
" O
isochore I-GENE
H1 I-GENE
" O
and O
the O
other O
segment O
( O
39 O
% O
GC I-GENE
in O
human I-GENE
, O
40 I-GENE
% O
GC I-GENE
in O
mouse I-GENE
) O
to O
" O
isochore I-GENE
L1 I-GENE
/ I-GENE
L2 O
". O

A I-GENE
review O
of O
the O
literature O
identified O
8 O
comprehensive I-GENE
clinical O
studies O
, O
all O
of O
which O
failed O
to O
document I-GENE
any O
relationship O
between O
NF1 I-GENE
and O
intracranial I-GENE
aneurysms I-GENE
. O

Serial I-GENE
US O
images O
were O
obtained O
before O
and O
20 O
, O
30 O
, O
40 I-GENE
, O
50 O
, O
60 O
, O
90 O
, O
120 O
, O
150 O
, O
180 O
, O
240 O
, O
and O
300 O
s O
after O
intravenous O
injection O
of O
2 I-GENE
g O
of O
contrast O
agent O
using O
conventional O
and O
harmonic I-GENE
PD I-GENE
US O
. O

Eight O
CAD I-GENE
patients O
who O
were O
matched O
to O
the O
treated O
patients O
for O
age O
(+/- O
3 I-GENE
years O
), O
baseline O
low O
density I-GENE
lipoprotein I-GENE
(+/- O
5 I-GENE
mg O
/ I-GENE
dL O
), O
and O
triglycerides I-GENE
(+/- O
50 O
mg O
/ I-GENE
dL O
) O
but O
who O
had O
never O
been O
treated O
with O
lipid O
- I-GENE
lowering O
drugs O
were O
selected O
as O
controls O
. O

Here O
we O
present O
evidence O
that O
the O
distal O
half O
( O
Stem I-GENE
2 I-GENE
) O
of O
the O
conserved O
base O
- I-GENE
paired I-GENE
stem O
structure O
found O
in O
all O
hY I-GENE
RNAs I-GENE
also O
plays O
a O
critical O
role O
in O
the O
export O
process O
. O

The O
contrasting I-GENE
effects O
of O
dopaminergic O
stimulation O
on O
the O
motor O
performance O
and O
on O
some O
aspects O
of O
cognitive O
processing O
suggest O
the O
existence O
of O
complex I-GENE
interactions O
within O
pre I-GENE
- I-GENE
and O
postsynaptic I-GENE
brain O
dopamine I-GENE
receptors I-GENE
, O
and O
an O
intervention O
of O
segregated I-GENE
basal O
ganglia I-GENE
- I-GENE
prefrontal I-GENE
cortex O
loops O
in O
motor O
and O
cognitive O
behaviour O
. O

The O
size O
of O
the O
infarct O
was O
determined O
using O
the O
creatine I-GENE
kinase I-GENE
integral I-GENE
method O
. O

These O
corrections I-GENE
do O
not O
involve O
sequences I-GENE
predicted O
to O
function O
as O
transcription I-GENE
factor I-GENE
binding I-GENE
sites I-GENE
. O

A I-GENE
comprehensive I-GENE
neuropsychological I-GENE
battery O
was O
administered O
to O
48 O
veterans I-GENE
with O
Gulf I-GENE
War I-GENE
Illness I-GENE
( O
GWI I-GENE
) O
characterized O
by O
severe O
fatigue I-GENE
( O
GV I-GENE
- I-GENE
F I-GENE
) O
and O
39 O
healthy O
veterans I-GENE
( O
GV I-GENE
- I-GENE
H I-GENE
). O

Quantitative O
PCR O
studies O
indicated O
that O
synthesis O
and O
transport O
of O
vector O
DNA I-GENE
into O
the O
nucleus O
were O
similar O
for O
macrophages O
infected O
with O
the O
clone O
239 O
and O
316 I-GENE
pseudotypes I-GENE
, O
suggesting O
that O
the O
restriction I-GENE
for O
SIVmac239 I-GENE
infection O
is O
after O
reverse I-GENE
transcription I-GENE
and O
nuclear I-GENE
import O
of O
viral I-GENE
DNA I-GENE
. O

EXAFS I-GENE
measurements O
around O
the O
Ge I-GENE
- I-GENE
K I-GENE
edge I-GENE
have O
been O
carried O
out O
for O
liquid O
Ge I-GENE
- I-GENE
Si I-GENE
alloys I-GENE
for O
the O
first O
time O
to O
investigate O
the O
local O
structure O
around O
a O
Ge I-GENE
atom I-GENE
. O

Hp I-GENE
positive O
relatives I-GENE
of O
gastric O
cancer O
had O
a O
markedly O
higher O
prevalence O
of O
atrophy O
than O
those O
with O
Hp I-GENE
negativity I-GENE
without O
cancer O
relatives I-GENE
( O
29 O
vs O
. O

Thus O
, O
replication O
fork I-GENE
movement O
near O
HML I-GENE
pauses I-GENE
at O
a O
silent I-GENE
origin O
which O
is O
competent O
for O
replication O
initiation I-GENE
but O
kept O
silent I-GENE
through O
Orc2p I-GENE
, O
a O
component O
of O
the O
replication O
initiator O
. O

Cardiac I-GENE
markers O
troponin I-GENE
T I-GENE
, O
CK I-GENE
- I-GENE
MB I-GENE
mass O
and O
myoglobin I-GENE
were O
helpful O
in O
the O
differential O
diagnosis O
of O
chest O
pain O
, O
even O
when O
the O
ECG O
was O
unremarkable I-GENE
or O
nonspecific O
. O

RESULTS O
: O
A I-GENE
novel O
gene I-GENE
was O
cloned O
. O

Both O
pancreatic O
and O
intestinal O
cell O
lines O
were O
found O
to O
express O
a O
number O
of O
POU I-GENE
( O
OCT I-GENE
binding I-GENE
) O
homeodomain I-GENE
proteins I-GENE
examined O
by O
electrophoretic O
mobility I-GENE
shift O
assay O
. O

In O
conclusion O
, O
USPIO I-GENE
- I-GENE
enhanced O
MRI O
data O
were O
capable O
to O
characterize O
tumor I-GENE
microvessel I-GENE
properties O
in O
this O
breast O
cancer O
model O
: O
microvascular O
permeability I-GENE
( O
determined O
using O
USPIO I-GENE
) O
correlated O
significantly O
with O
tumor I-GENE
grade O
. O

Radiolabeled I-GENE
biantennary I-GENE
N I-GENE
- I-GENE
glycans I-GENE
synthesized O
by O
Pro I-GENE
(-) I-GENE
5Lec20 I-GENE
were O
proportionately I-GENE
less O
ricin I-GENE
- I-GENE
bound O
than O
similar O
species O
from O
parental O
CHO O
cells O
, O
and O
Lec20 I-GENE
cell O
extracts O
had O
a O
markedly O
reduced O
ability O
to O
transfer I-GENE
Gal I-GENE
to O
GlcNAc I-GENE
- I-GENE
terminating I-GENE
acceptors I-GENE
. O

CONCLUSION O
: O
The O
training O
of O
novices I-GENE
using O
MIST I-GENE
- I-GENE
VR I-GENE
yields O
quantifiable I-GENE
changes O
in O
skill I-GENE
that O
are O
transferable I-GENE
to O
a O
simple O
real O
task O
and O
are O
similar O
to O
the O
results O
achieved O
with O
conventional O
training O
. O

To O
investigate O
the O
convergent I-GENE
role O
of O
the O
insulin I-GENE
/ I-GENE
IGF I-GENE
- I-GENE
I I-GENE
effector O
pathway O
mediating O
bihormonal I-GENE
stimulation O
of O
LDL I-GENE
receptor I-GENE
promoter I-GENE
expression O
, O
transfected O
granulosa I-GENE
- I-GENE
luteal O
cells O
were O
pretreated O
for O
30 O
min O
with O
two O
specific I-GENE
inhibitors O
of O
phophatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
wortmannin O
( O
100 O
nM O
) O
and O
LY I-GENE
294002 I-GENE
( O
10 O
microM O
), O
or O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
, O
PD I-GENE
98059 I-GENE
( O
50 O
microM O
), O
U0126 I-GENE
( O
10 O
microM O
), O
or O
the O
latter O
' O
s O
inactive O
derivative O
, O
U0124 I-GENE
( O
10 O
microM O
). O

Instead O
, O
affective O
flattening I-GENE
was O
associated I-GENE
with O
both O
dopamine I-GENE
receptor I-GENE
sensitivity O
and O
psychomotor I-GENE
slowing I-GENE
. O

Other O
therapies I-GENE
are O
also O
available O
, O
including O
hypertonic I-GENE
saline O
solution O
, O
THAM I-GENE
( O
Tris I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
methyl O
- I-GENE
aminomethane I-GENE
) O
buffer I-GENE
, O
and O
high O
- I-GENE
dose O
barbiturates I-GENE
. O

CONCLUSION O
: O
There O
are O
no O
differences O
in O
the O
measurement O
data O
derived O
from O
this O
method O
and O
actual O
measurement O
data O
from O
an O
object I-GENE
created O
by O
the O
computer O
- I-GENE
aided I-GENE
dental O
design O
program O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
pathway O
activation O
occurs O
during O
transformation O
induced O
by O
a O
number O
of O
classical O
oncogenes I-GENE
, O
including O
Bcr I-GENE
/ I-GENE
Abl I-GENE
, O
Ras I-GENE
and O
Rac I-GENE
, O
and O
is O
necessary O
for O
full I-GENE
transforming I-GENE
potential O
. O

Our O
results O
indicate O
that O
Gab1 I-GENE
is O
involved O
in O
the O
control O
of O
egr I-GENE
- I-GENE
1 I-GENE
expression O
regulated O
by O
insulin I-GENE
. O

The O
human I-GENE
cytomegalovirus I-GENE
( O
HCMV I-GENE
) O
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 I-GENE
is O
a O
nuclear I-GENE
phosphoprotein I-GENE
that O
is O
believed O
to O
be O
a O
key O
regulator I-GENE
in O
both O
lytic O
and O
latent I-GENE
infections O
. O

Unexpectedly I-GENE
, O
Arg1 I-GENE
- I-GENE
expressing O
COS1 I-GENE
cells O
showed O
no O
significant O
proteinase I-GENE
activity O
to O
various O
synthesized O
substrates O
under O
neutral O
or O
acidic O
conditions O
in O
this O
study O
. O

METHODS O
: O
126 O
patients O
with O
histologically O
confirmed O
MFH I-GENE
were O
analyzed O
. O

Regression I-GENE
analyses O
showed O
that O
SOREMP I-GENE
dream I-GENE
occurrences I-GENE
were O
significantly O
related I-GENE
to O
the O
amount O
of O
REM O
sleep O
, O
while O
NREMP I-GENE
dream I-GENE
occurrences I-GENE
were O
related I-GENE
to O
arousals I-GENE
from O
NREM I-GENE
sleep O
. O

[ O
Diabetologia I-GENE
( O
2001 I-GENE
) O
44 I-GENE
[ O
Suppl I-GENE
3 I-GENE
]: I-GENE
B37 I-GENE
- I-GENE
B44 I-GENE
] O

RESULTS O
: O
In O
vivo O
, O
there O
was O
a O
wide O
distribution O
with O
the O
coefficient O
of O
variation O
( O
SD O
/ I-GENE
mean O
x O
100 O
%) O
for O
different O
valve O
sizes O
ranging O
from O
21 O
% O
to O
39 O
% O
in O
the O
St I-GENE
Jude I-GENE
Medical I-GENE
valve O
and O
from O
25 O
% O
to O
33 O
% O
in O
the O
Omnicarbon I-GENE
valve O
. O

A I-GENE
microsporidian I-GENE
, O
Nosema I-GENE
algerae I-GENE
Vavra I-GENE
and O
undeen I-GENE
, O
was O
found O
parasitizing I-GENE
larvae O
and O
adults O
of O
a O
laboratory O
colony I-GENE
of O
Culex I-GENE
pipiens I-GENE
L I-GENE
. O
originated I-GENE
from O
Gharbia I-GENE
Governorate I-GENE
. O

Nearly I-GENE
all O
isolates O
of O
S I-GENE
. O
intermedius I-GENE
and O
most O
isolates O
of O
S I-GENE
. O
constellatus I-GENE
, O
but O
only O
19 O
% O
of O
those O
of O
S I-GENE
. O
anginosus I-GENE
, O
were O
associated I-GENE
with O
abscess O
. O

One O
of O
the O
conserved O
RNA I-GENE
subdomains O
, O
designated O
P3 I-GENE
, O
has O
previously O
been O
shown O
to O
be O
required O
for O
nucleolar I-GENE
localization O
. O

A I-GENE
total O
of O
25 O
patients O
with O
malignant O
brain O
tumours O
were O
investigated O
. O

Interventions I-GENE
aimed O
at O
these O
specific I-GENE
mediators I-GENE
and O
processes O
may O
be O
successful O
in O
reducing O
the O
very O
significant O
human I-GENE
and O
economic I-GENE
costs O
of O
vascular I-GENE
access O
dysfunction O
. O

We O
used O
stored O
plasma I-GENE
samples O
from O
409 I-GENE
patients O
in O
the O
National O
Institute O
of O
Neurological I-GENE
Diseases I-GENE
and O
Stroke I-GENE
( O
NINDS I-GENE
) O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
Stroke I-GENE
Trial I-GENE
to O
examine O
the O
relationship O
between O
an O
apolipoprotein I-GENE
( O
Apo I-GENE
) O
E2 I-GENE
or O
an O
Apo I-GENE
E4 I-GENE
phenotype O
and O
a O
favorable I-GENE
outcome O
3 I-GENE
months O
after O
stroke O
, O
the O
risk O
of O
intracerebral I-GENE
hemorrhage O
, O
and O
the O
response O
to O
intravenous O
t I-GENE
- I-GENE
PA I-GENE
therapy O
. O

These O
results O
were O
robust I-GENE
to O
changes O
in O
the O
baseline O
assumptions I-GENE
of O
the O
model O
. O

Cis I-GENE
- I-GENE
acting O
CCAAT I-GENE
elements O
are O
frequently O
found O
in O
eukaryotic I-GENE
promoter I-GENE
regions O
. O

The O
binary I-GENE
and O
tertiary O
combinations O
of O
plant O
- I-GENE
derived O
molluscicides I-GENE
Azadirachta I-GENE
indica I-GENE
and O
Cedrus I-GENE
deodara I-GENE
oil O
with O
synergists I-GENE
MGK I-GENE
- I-GENE
264 O
, O
piperonyl I-GENE
butoxide I-GENE
( O
PB I-GENE
) O
and O
fruit I-GENE
powder I-GENE
of O
Embelia I-GENE
ribes I-GENE
were O
used O
against O
the O
Lymnaea I-GENE
acuminata I-GENE
. O

This O
article O
reports O
the O
design O
and O
development O
of O
an O
ECG O
simulator I-GENE
intended I-GENE
for O
use O
in O
the O
testing O
, O
calibration I-GENE
and O
maintenance O
of O
electrocardiographic I-GENE
equipment I-GENE
. O

Exchanging I-GENE
the O
human I-GENE
propeptide I-GENE
in O
this O
chimera I-GENE
with O
either O
the O
murine I-GENE
MIC I-GENE
- I-GENE
1 I-GENE
or O
TGF I-GENE
- I-GENE
beta1 I-GENE
propeptide I-GENE
resulted O
in O
secretion O
of O
the O
unprocessed I-GENE
, O
monomeric I-GENE
chimera I-GENE
, O
suggesting O
a O
specific I-GENE
interaction O
between O
the O
human I-GENE
MIC I-GENE
- I-GENE
1 I-GENE
propeptide I-GENE
and O
mature O
peptide I-GENE
. O

RESULTS O
: O
The O
analyzed O
fragment I-GENE
has O
significant O
activity O
in O
EpCAM I-GENE
positive O
cells O
, O
and O
it O
is O
regulated O
negatively O
by O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNFalpha I-GENE
). O

The O
mutant I-GENE
receptors I-GENE
, O
as O
well O
as O
sBMPR I-GENE
- I-GENE
IA O
, O
were O
expressed O
as O
fusion I-GENE
proteins I-GENE
with O
thioredoxin I-GENE
in O
Escherichia I-GENE
coli I-GENE
, O
and O
purified O
using O
reverse I-GENE
phase O
high O
performance O
liquid O
chromatography O
( O
RP I-GENE
- I-GENE
HPLC O
) O
after O
digestion O
with O
enterokinase I-GENE
. O

The O
dual O
specificity O
kinases I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
kinase I-GENE
( O
MKK I-GENE
) O
7 O
and O
MKK4 I-GENE
are O
the O
only O
molecules I-GENE
known O
to O
directly O
activate O
the O
stress O
kinases I-GENE
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
( O
SAPKs I-GENE
)/ O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
JNKs I-GENE
) O
in O
response O
to O
environmental O
or O
mitogenic O
stimuli O
. O

This O
unique O
work O
needs O
to O
be O
edited I-GENE
critically I-GENE
and O
afterwards I-GENE
translated O
into O
Urdu I-GENE
and O
other O
languages I-GENE
for O
the O
benefit O
of O
the O
present O
day O
students O
and O
scholars I-GENE
. O

RANTES I-GENE
( O
regulated O
upon O
activation O
, O
normally O
T I-GENE
- I-GENE
cell O
expressed O
and O
presumably O
secreted O
) O
is O
a O
CC O
chemokine I-GENE
which O
recruits I-GENE
and O
activates O
monocytes O
, O
lymphocytes O
, O
and O
eosinophils O
, O
all O
cell O
types O
present O
in O
the O
lung O
inflammatory O
infiltrate I-GENE
induced O
by O
RSV I-GENE
infection O
. O

Gabapentin I-GENE
for O
opiod I-GENE
- I-GENE
related I-GENE
myoclonus I-GENE
in O
cancer O
patients O
. O

Recently O
, O
it O
was O
shown O
that O
purified O
RAG1 I-GENE
/ I-GENE
2 I-GENE
proteins I-GENE
can O
cleave I-GENE
DNA I-GENE
hairpins I-GENE
in O
vitro O
, O
but O
the O
same O
activity O
was O
also O
described O
for O
a O
protein I-GENE
complex I-GENE
of O
the O
DNA I-GENE
repair I-GENE
proteins I-GENE
Nbs1 I-GENE
/ I-GENE
Mre11 I-GENE
/ I-GENE
Rad50 I-GENE
. O

APC I-GENE
- I-GENE
resistance O
was O
determined O
with O
a O
functional O
method O
with O
high O
sensitivity O
and O
specificity O
for O
the O
factor I-GENE
V I-GENE
Leiden I-GENE
mutation I-GENE
. O

A I-GENE
picture O
is O
emerging I-GENE
showing O
a O
gradient O
of O
function O
among O
p53 I-GENE
, O
p73 I-GENE
, O
p63 I-GENE
ranging O
from O
tumor I-GENE
suppression O
to O
development O
. O

High O
plasma I-GENE
AVP I-GENE
levels O
observed O
in O
the O
two O
cases O
suggest O
that O
SSRIs I-GENE
stimulate O
AVP I-GENE
secretion O
, O
thereby O
causing O
SIADH I-GENE
. O

Mutation O
of O
the O
octamer O
element I-GENE
also O
significantly O
reduced O
the O
ability O
of O
HDAC1 I-GENE
to O
confer O
repression O
of O
inducible I-GENE
HLA I-GENE
- I-GENE
DRA I-GENE
promoter I-GENE
activation O
. O

Requirements I-GENE
for O
the O
nuclear I-GENE
- I-GENE
cytoplasmic I-GENE
translocation O
of O
infected O
- I-GENE
cell O
protein I-GENE
0 O
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
1 I-GENE
. O

The O
system O
, O
designed O
to O
exploit I-GENE
the O
relatively O
constant O
small I-GENE
intestine O
transit O
time O
, O
consists O
of O
a O
drug O
- I-GENE
containing O
core I-GENE
coated I-GENE
with O
a O
polymeric I-GENE
matrix I-GENE
formed O
by O
a O
channeling I-GENE
agent O
( O
NaCl O
, O
mannitol I-GENE
, O
and O
Emdex I-GENE
) O
and O
an O
inert I-GENE
polymer I-GENE
( O
Eudragit I-GENE
RS100 I-GENE
). O

The O
activity O
of O
Rac1 I-GENE
leads O
to O
STAT3 I-GENE
translocation O
to O
the O
nucleus O
coincident I-GENE
with O
STAT3 I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
expression O
. O

Treatment O
of O
ischemic O
heart O
disease O
in O
the O
elderly O

To O
avoid O
misinterpretations I-GENE
, O
special O
reference O
values O
should O
be O
applied O
for O
preadolescents I-GENE
, O
at O
least O
with O
regard O
to O
FVC I-GENE
and O
FEV1 O
. O

STUDY I-GENE
OBJECTIVE O
: O
This O
study O
assessed O
several O
methodological I-GENE
aspects O
related I-GENE
to O
the O
quality O
of O
published O
controlled O
clinical O
trials O
( O
CCTs I-GENE
) O
in O
relation O
to O
the O
participation O
of O
an O
epidemiologist I-GENE
/ I-GENE
biostatistician I-GENE
( O
E I-GENE
/ I-GENE
B I-GENE
). O

To O
the O
best O
of O
our O
knowledge O
, O
SNTCS I-GENE
is O
highly O
malignant O
. O

Northern O
blot O
analysis O
with O
one O
of O
the O
PARNAs I-GENE
revealed O
a O
highly O
abundant O
signal I-GENE
of O
approximately O
2 I-GENE
. O
0 O
kilobases O
( O
kb O
) O
present O
in O
all O
cell O
lines O
tested O
. O

The O
effect O
of O
crude O
oil O
spillage I-GENE
on O
growth I-GENE
, O
productivity I-GENE
and O
nutrient O
uptake O
of O
maize I-GENE
( O
Zea I-GENE
mays I-GENE
L I-GENE
.) O
was O
assessed O
in O
a O
pot I-GENE
experiment O
using O
an O
Evwreni I-GENE
manifold I-GENE
sample O
of O
a O
petroleum I-GENE
development O
company I-GENE
, O
which O
had O
a O
specific I-GENE
gravity I-GENE
of O
0 O
. O
8778 I-GENE
. O

10 O
. O
0 O
+/- O
2 I-GENE
. O
0 O
pmol I-GENE
/ I-GENE
24 O
h O
, O
P I-GENE
< O
0 O
. O
01 O
) O
and O
remained O
elevated O
. O

Pitx2 I-GENE
rescues I-GENE
the O
GABAergic I-GENE
differentiation O
defect O
and O
partially O
rescues I-GENE
the O
axon I-GENE
guidance I-GENE
and O
behavioral O
phenotypes O
of O
unc I-GENE
- I-GENE
30 O
mutants I-GENE
, O
indicating O
a O
high O
degree O
of O
functional O
conservation O
between O
these O
evolutionarily O
related I-GENE
genes I-GENE
. O

Phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
potentiates O
, O
but O
does O
not O
trigger I-GENE
, O
T I-GENE
cell O
proliferation O
mediated O
by O
the O
IL I-GENE
- I-GENE
2 I-GENE
receptor I-GENE
. O

In O
addition O
, O
stonin I-GENE
2 I-GENE
binds O
to O
the O
C2B I-GENE
domains I-GENE
of O
synaptotagmins I-GENE
I I-GENE
and O
II I-GENE
. O

Sequence O
comparison O
and O
binding I-GENE
studies O
of O
the O
18 O
- I-GENE
bp O
MOK2 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
present O
in O
intron O
2 I-GENE
of O
human I-GENE
, O
bovine I-GENE
, O
and O
mouse I-GENE
IRBP I-GENE
genes I-GENE
show O
that O
the O
3 I-GENE
'- O
half O
sequence I-GENE
is O
the O
essential O
core I-GENE
element I-GENE
for O
MOK2 I-GENE
binding I-GENE
. O

Measurements O
were O
obtained O
: O
( O
i O
) O
just O
after O
the O
traumatic I-GENE
exposure O
( O
D0 I-GENE
); O
( O
ii O
) O
3 I-GENE
days O
after O
this O
first O
measurement O
( O
D3 I-GENE
); O
and O
( O
iii O
) O
30 O
days O
after O
( O
D30 I-GENE
). O

Long I-GENE
- I-GENE
term O
results O
with O
MACOP I-GENE
- I-GENE
B I-GENE
and O
radiation O
therapy O
for O
aggressive O
lymphomas O
] O
BACKGROUND O
: O
Long I-GENE
- I-GENE
term O
results O
are O
needed O
to O
evaluate O
chemotherapy O
regimens O
and O
prognostic O
factors I-GENE
in O
non O
- I-GENE
Hodgkin O
' O
s O
lymphomas O
( O
NHL I-GENE
). O

From O
the O
above O
results O
, O
we O
might O
infer I-GENE
that O
the O
seizure O
type I-GENE
of O
TLE I-GENE
and O
a O
high O
frequency O
of O
seizure O
are O
two O
major I-GENE
independent O
precipitate I-GENE
factors I-GENE
for O
abnormal O
latencies I-GENE
of O
P300 I-GENE
in O
the O
epileptic I-GENE
patients O
. O

Rapamycin I-GENE
( O
FRAP I-GENE
/ I-GENE
mTOR I-GENE
inhibitor I-GENE
) O
blocked O
4E I-GENE
- I-GENE
BP1 I-GENE
phosphorylation O
causing O
a O
predominance I-GENE
of O
the O
alpha I-GENE
( O
hypophosphorylated I-GENE
) O
band O
. O

We O
investigate O
the O
reaction O
kinetics O
of O
small I-GENE
spherical I-GENE
particles O
with O
inertia I-GENE
, O
obeying I-GENE
coalescence I-GENE
type I-GENE
of O
reaction O
, O
B I-GENE
+ I-GENE
B I-GENE
--> I-GENE
B I-GENE
, O
and O
being O
advected I-GENE
by O
hydrodynamical I-GENE
flows I-GENE
with O
time O
- I-GENE
periodic I-GENE
forcing I-GENE
. O

Corticosteroid I-GENE
- I-GENE
mediated O
transcriptional O
inhibition O
was O
greater O
for O
MR O
/ I-GENE
GR I-GENE
in O
combination O
than O
for O
MR O
or O
GR I-GENE
alone O
. O

These O
data O
define O
a O
conserved O
pathway O
wherein I-GENE
sequential O
histone I-GENE
modifications O
establish O
a O
" O
histone I-GENE
code O
" O
essential O
for O
the O
epigenetic I-GENE
inheritance I-GENE
of O
heterochromatin I-GENE
assembly O
. O

The O
bovine I-GENE
PGHS I-GENE
- I-GENE
2 I-GENE
cDNA I-GENE
was O
cloned O
by O
a O
combination O
of O
reverse I-GENE
transcription I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
and O
cDNA I-GENE
library O
screening O
. O

Telomerase I-GENE
is O
a O
ribonucleoprotein I-GENE
complex I-GENE
that O
synthesizes I-GENE
telomeric O
DNA I-GENE
onto O
chromosomes O
using O
its O
RNA I-GENE
component O
as O
template O
. O

The O
iterative I-GENE
method O
proposed O
by O
Bengtsson I-GENE
[ O
Appl I-GENE
. O

Several O
distinct O
apoptotic O
stimuli O
induce O
the O
expression O
and O
caspase I-GENE
- I-GENE
dependent I-GENE
cleavage O
of O
hTAF I-GENE
( O
II I-GENE
) O
80 O
delta I-GENE
. O
hTAF I-GENE
( O
II I-GENE
) O
80 O
delta I-GENE
, O
unlike O
hTAF I-GENE
( O
II I-GENE
) O
80 O
, O
forms O
a O
TFIID I-GENE
- I-GENE
like I-GENE
complex I-GENE
lacking O
hTAF I-GENE
( O
II I-GENE
) O
31 O
. O

With O
NEU I-GENE
overexpression O
, O
nodal O
control O
decreased O
from O
72 O
% O
to O
34 O
% O
( O
p O
= O
. O
008 I-GENE
). O

The O
mouse I-GENE
platelet I-GENE
- I-GENE
derived O
growth I-GENE
factor I-GENE
( O
PDGF I-GENE
) O
beta I-GENE
- I-GENE
receptor I-GENE
promoter I-GENE
contains O
a O
CCAAT I-GENE
motif I-GENE
, O
and O
NF I-GENE
- I-GENE
Y I-GENE
plays O
an O
essential O
role O
in O
its O
transcription I-GENE
. O

Biol O
. O

The O
loop I-GENE
domain I-GENE
of O
heat I-GENE
shock I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
dictates I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
specificity O
and O
responses O
to O
heat I-GENE
stress O
. O

This O
activation O
was O
then O
blocked O
by O
CGS I-GENE
12066A I-GENE
. O

Among O
the O
transcription I-GENE
factors I-GENE
known O
to O
interact O
with O
Groucho I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
only O
RUNX1 I-GENE
was O
appreciably I-GENE
downregulated I-GENE
by O
E2A I-GENE
- I-GENE
HLF I-GENE
. O

A I-GENE
new O
intron O
of O
476 I-GENE
base O
pairs O
was O
found O
in O
the O
middle I-GENE
of O
the O
5 I-GENE
'- O
untranslated O
leader O
sequence I-GENE
and O
was O
shown O
to O
robustly I-GENE
enhance O
the O
promoter I-GENE
activity O
. O

Our O
findings O
further O
our O
understanding O
of O
how O
ZBP I-GENE
- I-GENE
89 I-GENE
modulates I-GENE
cell O
proliferation O
and O
reveals O
a O
novel O
mechanism O
by O
which O
the O
p53 I-GENE
protein I-GENE
is O
stabilized O
. O

In O
the O
free O
- I-GENE
swimming O
rotatory I-GENE
test O
mice O
spend I-GENE
most O
of O
the O
time O
swimming O
close O
to O
the O
wall O
of O
the O
container I-GENE
attempting I-GENE
to O
escape I-GENE
from O
an O
aversive I-GENE
test O
situation I-GENE
. O

As O
well O
, O
mixtures I-GENE
of O
( O
LA O
)( I-GENE
12 O
) O
with O
the O
longer O
chain I-GENE
PEs I-GENE
exhibit O
unusual O
biomodal I-GENE
enthalpy I-GENE
variations O
, O
suggesting O
peptide I-GENE
immiscibility I-GENE
in O
thicker I-GENE
gel O
state O
bilayers I-GENE
. O

At O
the O
time O
of O
the O
blind O
therapeutic O
doses O
, O
Tg I-GENE
- I-GENE
off O
values O
ranged O
from O
8 O
to O
608 I-GENE
microg O
/ I-GENE
l O
. O

Nephrotoxicity I-GENE
after O
orthotopic I-GENE
liver O
transplantation O
in O
cyclosporin O
A I-GENE
and O
FK O
506 I-GENE
- I-GENE
treated O
patients O
. O

In O
contrast O
to O
MPc3 I-GENE
, O
data O
indicate O
that O
the O
Pc I-GENE
protein I-GENE
M33 I-GENE
does O
not O
interact O
with O
AF9 I-GENE
. O

Hydrocoele I-GENE
is O
common O
in O
men O
in O
Wuchereria I-GENE
bancrofti I-GENE
- I-GENE
endemic I-GENE
areas O
, O
the O
treatment O
for O
which O
is O
currently O
surgical O
intervention O
. O

Of O
the O
patients O
in O
each O
regimen O
who O
reached O
study O
end O
points O
, O
17 O
of O
29 O
( O
59 O
%) O
were O
in O
regimen O
A I-GENE
, O
11 O
of O
20 O
( O
55 O
%) O
were O
in O
regimen O
B I-GENE
, O
and O
28 O
of O
43 I-GENE
( O
65 O
%) O
were O
in O
regimen O
C I-GENE
met I-GENE
the O
treatment O
success O
criterion O
. O

One O
maternal I-GENE
death O
, O
reduced O
body O
weight O
, O
and O
reduced O
weight O
gain O
were O
noted O
at O
the O
high O
dose O
; O
confirmed O
pregnancy O
rates O
were O
84 O
to O
100 O
% O
for O
each O
group O
. O

Karger I-GENE
AG I-GENE
, O
Basel I-GENE

In O
regards I-GENE
to O
the O
latter O
activity O
, O
it O
has O
been O
shown O
that O
S3 I-GENE
contains O
vigorous I-GENE
N I-GENE
- I-GENE
glycosylase I-GENE
activity O
for O
the O
removal O
of O
8 O
- I-GENE
oxoguanine I-GENE
residues O
in O
DNA I-GENE
that O
leaves O
baseless I-GENE
sites I-GENE
in O
their O
places I-GENE
. O

We O
describe O
a O
total O
of O
39 O
DEAH I-GENE
helicases I-GENE
in O
these O
four O
species O
. O

A I-GENE
prospective O
trial O
was O
undertaken O
to O
determine O
( O
1 I-GENE
) O
clinical O
characteristics O
of O
patients O
with O
chest O
pain O
; O
( O
2 I-GENE
) O
value O
of O
cardiac O
markers O
troponin I-GENE
T I-GENE
, O
myoglobin I-GENE
and O
CK I-GENE
- I-GENE
MB I-GENE
mass O
in O
differentiating O
cardiac O
and O
noncardiac I-GENE
chest O
pain O
; O
( O
3 I-GENE
) O
the O
proportion O
of O
patients O
with O
ACS I-GENE
in O
whom O
these O
markers O
provided O
helpful O
additional O
information O
on O
admission O
and O
afterwards I-GENE
. O

Inactivity I-GENE
of O
the O
human I-GENE
cytomegalovirus I-GENE
( O
HCMV I-GENE
) O
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
regulatory I-GENE
region O
( O
MIERR I-GENE
), O
which O
is O
composed O
of O
promoter I-GENE
, O
enhancer I-GENE
, O
unique O
region O
, O
and O
modulator I-GENE
, O
is O
linked O
to O
lack O
of O
HCMV I-GENE
replication O
in O
latently I-GENE
infected O
cells O
and O
in O
other O
nonpermissive I-GENE
cell O
types O
, O
including O
human I-GENE
embryonal I-GENE
NTera2 I-GENE
carcinoma O
( O
NT2 I-GENE
) O
cells O
. O

The O
observed O
triplexes I-GENE
depend O
on O
the O
length I-GENE
of O
the O
repeat I-GENE
. O

Statistical I-GENE
Analysis O
included O
ANOVA I-GENE
, O
the O
Pearson I-GENE
Product I-GENE
Moment I-GENE
Correlation I-GENE
Coefficient I-GENE
, O
Principal I-GENE
Components I-GENE
Analysis O
and O
Discriminant I-GENE
Function I-GENE
Analysis O
and O
the O
calculation I-GENE
of O
Cronbach I-GENE
' O
s O
alpha I-GENE
( O
alpha I-GENE
) O
RESULTS O
: O
Both O
Sensitivity I-GENE
and O
specificity O
exceed I-GENE
90 O
. O
00 O
at O
23 O
/ I-GENE
24 O
, O
Chronbach I-GENE
' O
s O
alpha I-GENE
for O
the O
total O
scale O
was O
equal O
to O
0 O
. O
95 O
. O

BACKGROUND O
: O
Previous O
studies O
have O
indicated O
that O
the O
60 O
-, I-GENE
30 O
-, I-GENE
28 O
- I-GENE
and O
12 O
- I-GENE
item I-GENE
versions I-GENE
of O
the O
General I-GENE
Health O
Questionnaire I-GENE
( O
GHQ I-GENE
) O
are O
liable I-GENE
to O
retest I-GENE
effects O
, O
especially O
when O
administered O
multiple O
times O
with O
short O
intervals O
. O

Cross O
- I-GENE
linking O
FcalphaR I-GENE
on O
wt I-GENE
- I-GENE
ITAM I-GENE
or O
IIA I-GENE
- I-GENE
ITAM I-GENE
cells O
triggered O
equivalent O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
- I-GENE
dependent I-GENE
activation O
of O
PKBalpha I-GENE
. O

An O
F222W I-GENE
: O
W21F I-GENE
rGST I-GENE
A1 I-GENE
- I-GENE
1 I-GENE
double O
mutant I-GENE
provides O
a O
direct O
fluorescence O
probe O
of O
changes O
in O
the O
environment O
of O
the O
C I-GENE
- I-GENE
terminal I-GENE
residue O
. O

Binding O
of O
serum I-GENE
response O
factor I-GENE
to O
CArG I-GENE
box I-GENE
sequences I-GENE
is O
necessary O
but O
not O
sufficient O
to O
restrict I-GENE
gene I-GENE
expression O
to O
arterial O
smooth I-GENE
muscle O
cells O
. O

They O
consist O
of O
at O
least O
two O
separable I-GENE
components O
, O
one O
heat I-GENE
stable O
and O
the O
other O
heat I-GENE
labile I-GENE
. O

No O
preferential O
VH I-GENE
/ I-GENE
VL I-GENE
- I-GENE
chains I-GENE
correlated O
with O
any O
of O
the O
12 O
different O
antigen I-GENE
reactivities I-GENE
, O
even O
for O
mAbs I-GENE
with O
nearly O
identical O
cross O
- I-GENE
reactivities I-GENE
. O

These O
results O
were O
compared O
with O
the O
estimates O
of O
penetration O
from O
steady O
- I-GENE
state O
calculations I-GENE
, O
square O
root O
of O
time O
calculations I-GENE
, O
and O
a O
biologically O
based O
mathematical I-GENE
model O
. O

Based O
on O
this O
analysis O
, O
we O
propose O
that O
the O
interactions O
of O
Sos I-GENE
with O
the O
switch O
1 I-GENE
and O
switch O
2 I-GENE
regions O
of O
Ras I-GENE
have O
distinct O
functional O
consequences O
: O
the O
interaction O
with O
switch O
2 I-GENE
mediates O
the O
anchoring I-GENE
of O
Ras I-GENE
to O
Sos I-GENE
, O
whereas O
the O
interaction O
with O
switch O
1 I-GENE
leads O
to O
disruption O
of O
the O
nucleotide I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
GDP I-GENE
dissociation O
. O

Thus O
, O
the O
interaction O
of O
Tat I-GENE
with O
the O
components O
of O
this O
rel I-GENE
/ I-GENE
AP1 I-GENE
cooperative O
complex I-GENE
seems O
to O
induce O
quantitative O
and O
qualitative O
alterations O
of O
this O
complex I-GENE
as O
activation O
progresses I-GENE
, O
resulting O
in O
a O
decrease O
of O
IL I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription I-GENE
. O

SIT I-GENE
( O
SHP2 I-GENE
- I-GENE
interacting I-GENE
transmembrane I-GENE
adaptor I-GENE
protein I-GENE
) O
is O
a O
recently O
identified O
transmembrane I-GENE
adaptor I-GENE
protein I-GENE
, O
which O
is O
expressed O
in O
lymphocytes O
. O

In O
this O
manuscript I-GENE
we O
demonstrate O
that O
two O
tandem O
Ets I-GENE
sites I-GENE
in O
the O
mouse I-GENE
GL I-GENE
alpha I-GENE
promoter I-GENE
bind O
the O
transcription I-GENE
factors I-GENE
Elf I-GENE
- I-GENE
1 I-GENE
and O
PU I-GENE
. O
1 I-GENE
, O
and O
that O
the O
3 I-GENE
' O
site I-GENE
is O
essential O
for O
expression O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
driven O
by O
the O
GL I-GENE
alpha I-GENE
promoter I-GENE
. O

ICA I-GENE
in O
the O
reference O
solution O
was O
characterised I-GENE
by O
LC I-GENE
and O
time O
- I-GENE
of O
- I-GENE
flight I-GENE
( O
TOF O
) O
MS O
and O
quantified I-GENE
by O
LC I-GENE
chemiluminescent I-GENE
nitrogen O
detection O
( O
LC I-GENE
- I-GENE
CLND I-GENE
). O

These O
disorders O
include O
low O
- I-GENE
back O
pain O
, O
saddle I-GENE
anesthesia O
, O
bilateral O
sciatica I-GENE
, O
then O
motor O
weakness I-GENE
of O
the O
lower O
extremities I-GENE
or O
chronic O
paraplegia I-GENE
and O
, O
bladder O
dysfunction O
. O

C I-GENE
. O
elegans I-GENE
embryogenesis O
begins O
with O
a O
stereotyped I-GENE
sequence I-GENE
of O
asymmetric O
cell O
divisions I-GENE
that O
are O
largely O
responsible O
for O
establishing I-GENE
the O
nematode O
body O
plan I-GENE
. O

Additionally O
, O
a O
CaCO3 I-GENE
- I-GENE
CO2 O
/ I-GENE
N2 O
buffered I-GENE
solution O
was O
necessary O
to O
maintain O
a O
pH O
of O
8 O
. O

Mss4 I-GENE
also O
acts O
as O
a O
relatively O
inefficient O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
GEF I-GENE
). O

Effects O
of O
3 I-GENE
' O
terminus O
modifications O
on O
mRNA I-GENE
functional O
decay O
during O
in O
vitro O
protein I-GENE
synthesis O
. O

Disciplinary I-GENE
action O
for O
DNA I-GENE
violation I-GENE
. O

This O
is O
necessary O
if O
psychiatric O
diagnoses I-GENE
are O
ultimately I-GENE
going I-GENE
to O
be O
refined I-GENE
and O
validated I-GENE
against O
biological O
criteria O
. O

We O
also O
demonstrate O
that O
the O
spo20 I-GENE
(+) I-GENE
gene I-GENE
product I-GENE
is O
structurally O
homologous O
to O
Saccharomyces I-GENE
cerevisiae I-GENE
Sec14 I-GENE
, O
the O
major I-GENE
phosphatidylinositol I-GENE
transfer I-GENE
protein I-GENE
of O
budding I-GENE
yeast I-GENE
. O

In O
addition O
, O
another O
derivative O
of O
pCMVJS21 I-GENE
( O
pCMVJS21DeltaGP I-GENE
) O
in O
which O
the O
gag I-GENE
, O
pol I-GENE
( O
and O
orf I-GENE
- I-GENE
x O
) O
coding O
sequences I-GENE
were O
deleted O
also O
gave O
transformed O
foci I-GENE
. O

It O
is O
shown O
that O
, O
for O
any O
periodic I-GENE
input O
, O
the O
map O
representing O
the O
relation O
between O
input O
phases O
at O
consecutive O
discharge O
times O
can O
be O
restricted O
to O
a O
piecewise I-GENE
continuous O
, O
orientation O
preserving I-GENE
circle I-GENE
map O
. O

Decreased I-GENE
serum I-GENE
ceruloplasmin I-GENE
and O
copper I-GENE
levels O
in O
cervical O
dystonia I-GENE
. O

Northern O
blot O
analysis O
of O
RNAs I-GENE
from O
a O
number O
of O
mouse I-GENE
tissues O
reveals O
that O
Atp6i I-GENE
is O
expressed O
predominantly O
in O
osteoclasts I-GENE
, O
and O
this O
predominant O
expression O
was O
confirmed O
by O
reverse I-GENE
- I-GENE
transcription I-GENE
polymerase I-GENE
chain I-GENE
reaction O
( O
RT I-GENE
- I-GENE
PCR O
) O
assay O
and O
immunohistochemical O
analysis O
. O

Behavioural I-GENE
tests O
with O
192 I-GENE
specimen I-GENE
of O
the O
roman I-GENE
garden I-GENE
snail I-GENE
Helix I-GENE
pomatia I-GENE
L I-GENE
. O
were O
performed O
in O
order O
to O
clarify O
whether O
the O
thermopreferendum I-GENE
of O
this O
pulmonate I-GENE
is O
influenced O
not O
only O
by O
the O
temperature O
of O
the O
substratum I-GENE
but O
also O
by O
air O
temperature O
. O

As O
well O
, O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
induced O
expression O
of O
IRF I-GENE
- I-GENE
1 I-GENE
and O
its O
binding I-GENE
to O
the O
IRF I-GENE
element I-GENE
is O
inhibited O
. O

Baseline I-GENE
BMD O
values O
were O
significantly O
lower O
in O
the O
oligo I-GENE
- I-GENE
amenorrheic I-GENE
group O
than O
in O
the O
two O
others O
at O
the O
level O
of O
lumbar O
spine O
( O
anteroposterior O
view O
: O
0 O
. O
941 I-GENE
+/- O
0 O
. O
039 I-GENE
in O
oligo I-GENE
- I-GENE
amenorrheic I-GENE
vs O
1 I-GENE
. O
077 I-GENE
+/- O
0 O
. O
029 I-GENE
or O
1 I-GENE
. O
051 I-GENE
+/- O
0 O
. O
017 I-GENE
g O
x O
cm O
(- O
2 I-GENE
), O
P I-GENE
< O
0 O
. O
005 O
, O
in O
the O
eumenorrheic I-GENE
and O
contraceptive I-GENE
user I-GENE
groups O
, O
respectively O
) O
but O
not O
in O
weight O
- I-GENE
bearing O
bone O
such O
as O
proximal I-GENE
and O
midshaft I-GENE
femur O
. O

The O
glucose O
/ I-GENE
insulin I-GENE
stimulation O
was O
inhibited O
by O
the O
addition O
of O
polyunsaturated I-GENE
fatty I-GENE
acids O
. O

We O
report O
the O
results O
of O
a O
detailed O
policy I-GENE
analysis O
comparing O
2 I-GENE
CJD I-GENE
- I-GENE
related I-GENE
decisions I-GENE
: O
a O
1995 O
recall I-GENE
of O
blood O
from O
a O
donor O
with O
classic I-GENE
CJD I-GENE
and O
the O
1999 I-GENE
decision I-GENE
to O
defer I-GENE
donations I-GENE
from O
individuals O
with O
a O
6 I-GENE
- I-GENE
month O
travel I-GENE
history O
to O
the O
UK I-GENE
between O
1980 O
and O
1996 O
due O
to O
concerns I-GENE
related I-GENE
to O
variant I-GENE
CJD I-GENE
. O

The O
5 I-GENE
' O
flanking O
sequence I-GENE
of O
the O
3B I-GENE
gene I-GENE
is O
extremely O
A I-GENE
+ I-GENE
T I-GENE
rich O
but O
contains O
five O
G I-GENE
/ I-GENE
C I-GENE
rich O
stretches O
, O
each O
approximately O
7bp I-GENE
long O
, O
which O
have O
strong O
sequence I-GENE
similarity O
to O
the O
G I-GENE
boxes O
found O
upstream O
of O
other O
developmentally O
regulated O
Dictyostelium O
genes I-GENE
. O

PACAP I-GENE
mRNA I-GENE
was O
widely O
expressed O
in O
most O
human I-GENE
tissues O
; O
in O
transfected O
cells O
, O
PACAP I-GENE
was O
diffusely I-GENE
expressed O
in O
the O
cytoplasm O
. O

The O
proportion O
of O
the O
biopsies O
found O
to O
be O
seropositive O
for O
HBs I-GENE
antigen I-GENE
was O
27 O
. O
9 O
%, O
and O
these O
showed O
either O
MGN I-GENE
or O
MPGN I-GENE
pattern O
. O

In O
the O
present O
study O
, O
we O
have O
determined O
the O
ICBP90 I-GENE
gene I-GENE
structure O
by O
screening O
of O
a O
human I-GENE
placenta O
genomic O
library O
and O
PCR O
analysis O
. O

In O
the O
stable O
transfectants O
( O
BM3 I-GENE
cells O
) O
expressing O
a O
mutant I-GENE
bacterial I-GENE
P450 I-GENE
AA O
epoxygenase I-GENE
, O
F87V I-GENE
BM3 I-GENE
, O
which O
was O
genetically O
engineered I-GENE
to O
metabolize I-GENE
arachidonic I-GENE
acid I-GENE
only O
to O
14 O
, O
15 O
- I-GENE
EET I-GENE
, O
AA O
did O
not O
induce O
apoptosis O
and O
protected O
against O
agonist O
- I-GENE
induced O
apoptosis O
. O

The O
revitalization I-GENE
of O
surgery O
for O
Parkinson O
' O
s O
disease O
( O
PD I-GENE
) O
has O
fueled I-GENE
discussion O
about O
the O
best O
methodology I-GENE
to O
define O
the O
target O
. O

Foreigners I-GENE
return O
. O

She I-GENE
drank I-GENE
alcohol O
once O
or O
twice O
a O
week O
and O
regularly I-GENE
took I-GENE
an O
analgesic O
preparation O
, O
containing O
aspirin I-GENE
and O
acetaminophen I-GENE
, O
for O
alleviation I-GENE
of O
headaches I-GENE
. O

The O
authors O
did O
not O
detect O
any O
significant O
correlations O
between O
parameters O
of O
the O
lipids O
of O
bone O
marrow O
and O
leptin I-GENE
levels O
in O
serum I-GENE
and O
bone O
marrow O
. O

When O
the O
blood O
clot I-GENE
is O
formed O
in O
the O
vitreous O
cavity O
, O
intravitreal I-GENE
injection O
of O
t I-GENE
- I-GENE
PA I-GENE
can O
convert I-GENE
plasminogen I-GENE
to O
plasmin I-GENE
and O
remove I-GENE
the O
clot I-GENE
. O

When O
this O
CCAAT I-GENE
box I-GENE
was O
inserted O
into O
a O
heterologous O
promoter I-GENE
construct I-GENE
, O
OA I-GENE
induction O
was O
dependent I-GENE
on O
an O
intact O
CCAAT I-GENE
box I-GENE
. O

Encouraged I-GENE
by O
a O
Dutch I-GENE
study O
using O
etidronate I-GENE
/ I-GENE
fluoride O
in O
corticoid I-GENE
- I-GENE
induced O
osteoporosis I-GENE
, O
we O
performed O
a O
pilot I-GENE
study O
in O
33 O
men O
with O
severe O
established O
primary O
osteoporosis I-GENE
giving O
cyclically I-GENE
etidronate I-GENE
for O
14 O
days O
followed O
by O
fluoride O
plus O
calcium O
/ I-GENE
vitamin O
D I-GENE
for O
76 I-GENE
days O
. O

Far I-GENE
Western O
blot O
analysis O
suggested O
that O
the O
tandem O
SH2 I-GENE
domains I-GENE
of O
SHP2 I-GENE
bind O
to O
Gab1 I-GENE
in O
a O
specific I-GENE
orientation O
, O
in O
which O
the O
N I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
binds O
to O
phosphotyrosine I-GENE
( O
Tyr I-GENE
( O
P I-GENE
))- I-GENE
627 I-GENE
and O
the O
C I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
binds O
to O
Tyr I-GENE
( O
P I-GENE
)- I-GENE
659 I-GENE
. O

Electrophoretic O
mobility I-GENE
shift O
assays O
and O
coimmunoprecipitation I-GENE
studies O
suggest O
that O
homo I-GENE
- I-GENE
and O
heterodimerization O
occurs O
between O
cKrox I-GENE
family I-GENE
members O
. O

Expression O
of O
human I-GENE
RACK1 I-GENE
efficiently O
relieves I-GENE
E1A I-GENE
- I-GENE
mediated O
growth I-GENE
inhibition O
in O
HF7c I-GENE
and O
protects I-GENE
human I-GENE
tumor I-GENE
cells O
from O
E1A I-GENE
- I-GENE
induced O
apoptosis O
. O

By O
using O
space O
- I-GENE
discrete O
/ I-GENE
continuous O
metapopulation I-GENE
dynamic O
models O
and O
computer O
simulations I-GENE
, O
we O
show O
that O
there O
can O
be O
two O
principally I-GENE
different O
regimes I-GENE
of O
metapopulation I-GENE
dynamics O
. O

Arterial I-GENE
blood O
gas O
tensions I-GENE
were O
similar O
across O
all O
ventilation O
modes O
. O

Four O
casein I-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
are O
differentially O
partitioned I-GENE
between O
nucleus O
and O
cytoplasm O
. O

CONCLUSION O
: O
Extrusion I-GENE
cooking I-GENE
is O
effective O
for O
the O
inactivation O
of O
DON I-GENE
but O
is O
of O
limited O
value O
for O
AFB1 I-GENE
, O
even O
if O
metabisulphite I-GENE
is O
added O
. O

Also O
, O
the O
EWS I-GENE
protein I-GENE
stimulates O
transcription I-GENE
mediated O
by O
the O
COOH O
- I-GENE
terminal I-GENE
transactivation O
domain I-GENE
of O
the O
cofactor I-GENE
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
). O

HSF I-GENE
binds O
DNA I-GENE
as O
a O
trimer I-GENE
, O
and O
additional O
trimers I-GENE
can O
bind O
DNA I-GENE
co O
- I-GENE
operatively I-GENE
. O

Two O
cases O
with O
marked O
chronic O
arm O
lymphoedema I-GENE
reported O
major I-GENE
and O
persistent O
improvements I-GENE
in O
arm O
volume O
for O
at O
least O
12 O
months O
after O
treatment O
with O
HBO2 I-GENE
. O

Growth I-GENE
hormone I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
receptors I-GENE
in O
the O
temporomandibular I-GENE
joint O
of O
the O
rat I-GENE
. O

Folate I-GENE
metabolism O
in O
the O
human I-GENE
malaria O
parasite O
Plasmodium I-GENE
falciparum O
is O
an O
essential O
activity O
for O
cell O
growth I-GENE
and O
replication O
, O
and O
the O
target O
of O
an O
important O
class I-GENE
of O
therapeutic O
agents O
in O
widespread I-GENE
use O
. O

These O
results O
indicate O
that O
BACM I-GENE
has O
antiplaque I-GENE
and O
stronger O
antidegradation I-GENE
effects O
than O
GLCM I-GENE
. O

A I-GENE
mutation I-GENE
in O
the O
C I-GENE
domain I-GENE
of O
Rb I-GENE
, O
L901Q I-GENE
, O
has O
been O
identified O
that O
completely O
abolishes O
cdk4 I-GENE
/ I-GENE
D1 I-GENE
phosphorylation O
of O
the O
isolated O
C I-GENE
domain I-GENE
. O

Homo I-GENE
- I-GENE
oligomerisation I-GENE
and O
nuclear I-GENE
localisation I-GENE
of O
mouse I-GENE
histone I-GENE
deacetylase I-GENE
1 I-GENE
. O

Energy I-GENE
expenditure O
was O
obtained O
using O
a O
primed O
, O
3 I-GENE
- I-GENE
hour O
infusion O
of O
NaH I-GENE
( O
13 O
) O
CO I-GENE
( O
3 I-GENE
'), I-GENE
breath I-GENE
( O
13 O
) O
CO I-GENE
( O
2 I-GENE
) O
enrichment I-GENE
determination O
by O
isotope I-GENE
ratio O
mass O
spectroscopy O
, O
and O
the O
application O
of O
a O
standard O
regression O
equation O
. O

Fasting I-GENE
gastrin I-GENE
levels O
( O
normal O
range O
: O
25 O
- I-GENE
110 I-GENE
mU I-GENE
/ I-GENE
L I-GENE
) O
varied O
from O
48 O
. O
78 O
mU I-GENE
/ I-GENE
L I-GENE
- I-GENE
168 I-GENE
. O
20 O
( O
mean O
: O
85 O
. O
23 O
mU I-GENE
/ I-GENE
L I-GENE
). O

Identification O
of O
pulmonary O
vein O
stenosis O
after O
radiofrequency I-GENE
ablation O
for O
atrial I-GENE
fibrillation O
using O
MRI O
. O

The O
continuing I-GENE
development O
of O
ligands O
that O
function O
as O
selective O
estrogens I-GENE
or O
antiestrogens I-GENE
for O
ERalpha I-GENE
or O
ERbeta I-GENE
should O
allow O
optimized I-GENE
tissue I-GENE
selectivity O
of O
these O
agents O
for O
menopausal I-GENE
hormone I-GENE
replacement O
therapy O
and O
the O
treatment O
and O
prevention O
of O
breast O
cancer O
. O

Baseline I-GENE
variables O
associated I-GENE
with O
CD O
included O
a O
less O
frequent O
use O
of O
prestroke I-GENE
aspirin I-GENE
and O
a O
higher O
incidence O
of O
early I-GENE
CT I-GENE
changes O
of O
edema O
or O
mass O
effect O
or O
dense I-GENE
middle I-GENE
cerebral O
artery O
sign O
. O

A I-GENE
peculiar I-GENE
people O
: O
" O
the O
physiological O
aspects O
of O
Mormonism I-GENE
1850 I-GENE
- I-GENE
1975 I-GENE
." I-GENE

SH2D1A I-GENE
protein I-GENE
levels O
are O
up O
- I-GENE
regulated O
by O
CD40 I-GENE
cross O
- I-GENE
linking O
and O
down O
- I-GENE
regulated O
by O
B I-GENE
cell O
receptor I-GENE
ligation O
. O

The O
Genescan I-GENE
program O
predicted O
an O
open O
reading O
frame O
of O
a O
novel O
, O
intron O
- I-GENE
less O
gene I-GENE
adjacent O
to O
the O
B236 I-GENE
spot I-GENE
that O
encodes O
a O
putative O
493 I-GENE
- I-GENE
amino O
acid I-GENE
protein I-GENE
containing O
the O
SNAG I-GENE
repressor I-GENE
motif I-GENE
in O
the O
NH2 I-GENE
- I-GENE
terminal I-GENE
region O
and O
five O
C2H2 I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
motifs O
in O
the O
COOH O
- I-GENE
terminal I-GENE
half O
. O

Under O
our O
conditions O
, O
the O
combination O
O3 I-GENE
/ I-GENE
UV O
did O
not O
improve O
the O
degradation O
rate O
obtained O
by O
ozonation I-GENE
. O

The O
metabolic O
events O
occurring O
at O
or O
near O
that O
structure O
and O
involving O
cyclin I-GENE
D3 I-GENE
cause O
the O
translocation O
of O
ICP0 I-GENE
to O
the O
cytoplasm O
. O

In O
the O
single O
case O
the O
restoration I-GENE
of O
a O
structured O
daily O
routine O
represents O
the O
presupposition I-GENE
for O
a O
cognitive O
therapy O
. O

Immunofluorescence I-GENE
studies O
in O
C2C12 O
myotubes O
show O
that O
Smad2 I-GENE
and O
MEF2A I-GENE
co O
- I-GENE
localise I-GENE
in O
the O
nucleus O
of O
multinuclear I-GENE
myotubes O
during O
differentiation O
. O

In O
35 O
of O
those O
patients O
DD I-GENE
was O
measured O
also O
with O
microlatex I-GENE
tests O
-- O
Tinaquant I-GENE
and O
BC I-GENE
d O
- I-GENE
dimer O
. O

Simulating I-GENE
the O
impact O
during O
human I-GENE
jumping I-GENE
by O
means O
of O
a O
4 I-GENE
- I-GENE
degrees O
- I-GENE
of O
- I-GENE
freedom I-GENE
model O
with O
time O
- I-GENE
dependent I-GENE
properties O
. O

A I-GENE
novel O
approach O
was O
developed O
for O
identifying O
transcription I-GENE
factor I-GENE
activities O
associated I-GENE
with O
NGF I-GENE
- I-GENE
activated I-GENE
, O
but O
not O
EGF I-GENE
- I-GENE
activated I-GENE
, O
signaling O
, O
using O
random O
oligonucleotide I-GENE
clones O
from O
a O
DNA I-GENE
recognition I-GENE
library O
to O
isolate O
specific I-GENE
DNA I-GENE
binding I-GENE
proteins I-GENE
from O
PC12 O
nuclear I-GENE
extracts O
. O

Atheroma I-GENE
appears O
as O
a O
very O
low O
signal I-GENE
intensity O
area O
on O
2 I-GENE
- I-GENE
dimensional O
time O
- I-GENE
of O
- I-GENE
flight I-GENE
( O
TOF O
) O
magnetic O
resonance O
( O
MR O
) O
images O
, O
and O
its O
components O
have O
various O
signal I-GENE
intensities I-GENE
on O
spin O
- I-GENE
echo O
( O
SE O
) O
images O
. O

Finally O
a O
10 O
- I-GENE
nucleotide I-GENE
region O
flanking O
the O
exon O
4 I-GENE
protein I-GENE
- I-GENE
binding I-GENE
site I-GENE
is O
homologous O
to O
instability I-GENE
elements O
within O
five O
other O
transcripts I-GENE
, O
suggesting O
that O
a O
common O
coding O
region O
determinant O
may O
exist O
. O

Chronic O
nutritional O
diseases O
of O
infectious O
origin O
: O
an O
assessment O
of O
a O
nascent I-GENE
field O
. O

The O
cut I-GENE
- I-GENE
off O
percentage O
positivity I-GENE
value O
was O
established O
using O
500 O
brucellosis I-GENE
- I-GENE
positive O
and O
500 O
brucellosis I-GENE
- I-GENE
negative O
serum I-GENE
samples O
, O
confirmed O
with O
reference O
to O
the O
sample O
data O
using O
the O
indirect O
ELISA O
kit I-GENE
. O

PROCEDURE I-GENE
: O
Cannulas I-GENE
were O
surgically O
positioned O
in O
the O
abomasal I-GENE
body O
and O
pyloric I-GENE
antrum I-GENE
of O
each O
calf I-GENE
. O

The O
utilities I-GENE
measured O
in O
our O
study O
can O
be O
applied O
directly O
to O
quality O
- I-GENE
of O
- I-GENE
life O
determinations O
in O
clinical O
trials O
of O
adjuvant O
IFN I-GENE
alpha I-GENE
- I-GENE
2b I-GENE
to O
measure O
the O
net I-GENE
benefit O
of O
therapy O
. O

Cells I-GENE
lacking O
p116 I-GENE
exhibit O
a O
striking O
defect O
in O
the O
formation O
of O
these O
macropinocytic I-GENE
structures O
, O
a O
concomitant O
reduction O
in O
the O
rate O
of O
fluid O
phase O
pinocytosis I-GENE
, O
a O
significant O
decrease O
in O
the O
efficiency O
of O
chemotactic O
aggregation O
, O
and O
a O
decrease O
in O
cellular O
F I-GENE
- I-GENE
actin I-GENE
content O
. O

Ectopic I-GENE
expression O
of O
the O
dominant I-GENE
mutant I-GENE
Lg3 I-GENE
allele I-GENE
is O
believed O
to O
cause O
the O
phenotype O
. O

Specimen I-GENE
mass O
reduction O
increased O
with O
irradiance I-GENE
from O
19 O
to O
72 O
% O
of O
the O
initial O
mass O
for O
9 O
-- O
31 O
W I-GENE
/ I-GENE
cm O
( O
2 I-GENE
), O
respectively O
. O

Analysis O
of O
the O
genome O
sequence I-GENE
revealed O
26 O
, O
588 I-GENE
protein I-GENE
- I-GENE
encoding O
transcripts I-GENE
for O
which O
there O
was O
strong O
corroborating I-GENE
evidence O
and O
an O
additional O
approximately O
12 O
, O
000 O
computationally I-GENE
derived O
genes I-GENE
with O
mouse I-GENE
matches O
or O
other O
weak O
supporting O
evidence O
. O

The O
other O
inhibitor I-GENE
was O
a O
single O
TAR I-GENE
decoy I-GENE
, O
driven O
by O
the O
U6 I-GENE
small I-GENE
nuclear I-GENE
RNA I-GENE
promoter I-GENE
( O
U6 I-GENE
- I-GENE
P I-GENE
). O

By O
comparison O
, O
in O
nontumorigenic I-GENE
Ad5 I-GENE
cells O
, O
class I-GENE
I I-GENE
expression O
is O
high O
due O
to O
negligible I-GENE
binding I-GENE
of O
COUP I-GENE
- I-GENE
TF I-GENE
and O
strong O
binding I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

Moreover O
, O
a O
complex I-GENE
containing O
PTP I-GENE
phi I-GENE
, O
paxillin I-GENE
, O
and O
a O
paxillin I-GENE
- I-GENE
associated I-GENE
tyrosine I-GENE
kinase I-GENE
, O
Pyk2 I-GENE
, O
can O
be O
immunoprecipitated O
from O
macrophage I-GENE
lysates O
, O
and O
the O
catalytic O
domain I-GENE
of O
PTP I-GENE
phi I-GENE
selectively O
binds O
paxillin I-GENE
and O
Pyk2 I-GENE
in O
vitro O
. O

Our O
previous O
studies O
have O
shown O
that O
SHP I-GENE
- I-GENE
1 I-GENE
, O
a O
SH2 I-GENE
domain I-GENE
- I-GENE
containing O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
is O
expressed O
not O
only O
in O
cells O
of O
hematopoietic I-GENE
lineages O
, O
but O
also O
in O
many O
non O
- I-GENE
hematopoietic I-GENE
cells O
under O
the O
control O
of O
an O
alternative O
tissue I-GENE
- I-GENE
specific I-GENE
promoter I-GENE
, O
P1 I-GENE
. O

Whereas O
Smad2 I-GENE
was O
rapidly O
phosphorylated O
by O
TGF I-GENE
- I-GENE
beta I-GENE
and O
involved O
in O
the O
initial O
activation O
of O
Agc I-GENE
expression O
in O
confluent I-GENE
cells O
, O
Smad2 I-GENE
activation O
was O
not O
required O
for O
maintaining O
the O
high O
level O
of O
Agc I-GENE
expression O
. O

The O
astronaut I-GENE
crew I-GENE
operates I-GENE
the O
payload I-GENE
and O
documents I-GENE
its O
operation O
. O

This O
molecule I-GENE
, O
wH22xeGFP I-GENE
, O
consists O
of O
the O
entire O
humanized I-GENE
anti I-GENE
- I-GENE
FcgammaRI I-GENE
mAb I-GENE
H22 I-GENE
with O
eGFP I-GENE
genetically O
fused O
to O
the O
C I-GENE
- I-GENE
terminal I-GENE
end O
of O
each O
CH3 I-GENE
domain I-GENE
. O
wH22xeGFP I-GENE
binds O
within O
the O
ligand O
- I-GENE
binding I-GENE
region O
by O
its O
Fc I-GENE
end O
, O
as O
well O
as O
outside O
the O
ligand O
- I-GENE
binding I-GENE
region O
by O
its O
Fab I-GENE
ends O
, O
thereby O
cross O
- I-GENE
linking O
FcgammaRI I-GENE
. O

On O
the O
other O
hand O
, O
hepatic I-GENE
arterial O
infusion O
therapy O
prolongs I-GENE
the O
survival O
of O
H3 I-GENE
patients O
only O
. O

Hepatitis I-GENE
B I-GENE
and O
C I-GENE
seroprevalence I-GENE
rates O
among O
high O
- I-GENE
risk O
adolescents I-GENE
are O
lower O
in O
El I-GENE
Paso I-GENE
than O
in O
other O
similar O
US O
populations O
, O
presenting O
an O
ideal I-GENE
climate I-GENE
for O
prevention O
programs O
. O

We O
found O
that O
the O
SOCS I-GENE
box I-GENE
interacted O
with O
Cullin I-GENE
- I-GENE
2 I-GENE
and O
promoted O
ubiquitination O
of O
TEL I-GENE
- I-GENE
JAK2 I-GENE
. O

A I-GENE
patient O
is O
described O
with O
skin O
lesions O
resembling O
Kaposi O
' O
s O
sarcoma I-GENE
( O
KS O
). O

Special I-GENE
issues O
devoted I-GENE
to O
the O
biosynthesis O
of O
woody I-GENE
plant O
biopolymers I-GENE
and O
related I-GENE
substances O
. O

These O
data O
suggest O
that O
ADAM I-GENE
- I-GENE
TS12 I-GENE
may O
play O
roles O
in O
pulmonary O
cells O
during O
fetal O
development O
or O
in O
tumor I-GENE
processes O
through O
its O
proteolytic O
activity O
or O
as O
a O
molecule I-GENE
potentially O
involved O
in O
regulation O
of O
cell O
adhesion I-GENE
. O

Progressive I-GENE
study O
and O
robustness I-GENE
test O
of O
QSAR I-GENE
model O
based O
on O
quantum I-GENE
chemical O
parameters O
for O
predicting O
BCF I-GENE
of O
selected O
polychlorinated I-GENE
organic O
compounds O
( O
PCOCs I-GENE
). O

Additional I-GENE
deletion O
mutations O
revealed O
a O
new O
, O
67 O
- I-GENE
amino O
- I-GENE
acid I-GENE
functional O
domain I-GENE
within O
the O
proline O
- I-GENE
rich O
region O
of O
SLP I-GENE
- I-GENE
76 I-GENE
, O
which O
we O
have O
termed O
the O
P I-GENE
- I-GENE
1 I-GENE
domain I-GENE
. O

Patients O
with O
type I-GENE
III I-GENE
SOD I-GENE
may O
have O
visceral O
hyperalgesia I-GENE
; O
a O
trial O
of O
antidepressants I-GENE
or O
a O
therapeutic O
trial O
with O
botulinum I-GENE
toxin I-GENE
injection O
into O
the O
ampulla I-GENE
should O
be O
considered O
prior O
to O
more O
invasive O
endoscopic I-GENE
therapy O
. O

We O
have O
now O
tested O
all O
known O
mammalian I-GENE
Groucho I-GENE
family I-GENE
members O
for O
their O
ability O
to O
interact O
specifically O
with O
individual O
Tcf I-GENE
/ I-GENE
Lef I-GENE
family I-GENE
members O
. O

Body I-GENE
weight O
reduction O
increases O
insulin I-GENE
sensitivity O
and O
improves I-GENE
both O
blood O
glucose O
and O
blood O
pressure O
control O
. O

Sequence O
analysis O
indicates O
that O
RBP21 I-GENE
shares O
homology I-GENE
with O
other O
retinoblastoma I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
in O
the O
pRb I-GENE
- I-GENE
binding I-GENE
motif I-GENE
LxCxE I-GENE
at O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
. O

Tolerance I-GENE
in O
renal O
transplantation O
after O
allogeneic I-GENE
bone O
marrow O
transplantation O
- I-GENE
6 I-GENE
- I-GENE
year O
follow O
- I-GENE
up O
. O

By O
analyzing O
5 I-GENE
'- O
deletion O
insulin I-GENE
promoter I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
in O
transient O
transfections O
of O
clonal I-GENE
INS I-GENE
- I-GENE
1 I-GENE
beta I-GENE
- I-GENE
cells O
, O
we O
located O
activating I-GENE
Hh I-GENE
- I-GENE
responsive I-GENE
regions O
within O
the O
rat I-GENE
insulin I-GENE
I I-GENE
promoter I-GENE
that O
include O
the O
glucose O
- I-GENE
response O
elements O
Far I-GENE
( O
E2 I-GENE
) O
and O
Flat I-GENE
( O
A2 I-GENE
/ I-GENE
A3 I-GENE
). O

However O
, O
when O
directed O
to O
the O
nucleosome I-GENE
by O
fusion I-GENE
to O
core I-GENE
histone I-GENE
H2A I-GENE
or O
H2B I-GENE
, O
the O
non O
- I-GENE
histone I-GENE
tail O
forms O
an O
MCB I-GENE
that O
appears O
identical O
to O
that O
of O
the O
endogenous I-GENE
protein I-GENE
. O

Data O
were O
obtained O
from O
2 I-GENE
undergraduate I-GENE
student I-GENE
samples O
, O
a O
self O
- I-GENE
report O
group O
( O
n O
= O
132 O
) O
who O
provided O
NEO I-GENE
- I-GENE
PI I-GENE
- I-GENE
R I-GENE
self O
- I-GENE
ratings I-GENE
on O
2 I-GENE
occasions I-GENE
separated O
by O
a O
7 O
- I-GENE
to O
14 O
- I-GENE
day O
interval O
and O
an O
informant I-GENE
group O
( O
n O
= O
109 I-GENE
) O
who O
provided O
ratings I-GENE
of O
well O
- I-GENE
known O
friends I-GENE
or O
relatives I-GENE
on O
2 I-GENE
occasions I-GENE
separated O
by O
a O
6 I-GENE
month O
interval O
. O

Pulmonary I-GENE
embolectomy I-GENE
and O
lung O
transplantation O
are O
the O
main O
indications I-GENE
for O
the O
use O
of O
heart O
- I-GENE
lung O
- I-GENE
machine O
. O

Comparison O
of O
German I-GENE
language O
versions I-GENE
of O
the O
QWB I-GENE
- I-GENE
SA O
and O
SF I-GENE
- I-GENE
36 O
evaluating O
outcomes O
for O
patients O
with O
prostate O
disease O
. O

The O
median O
preoperative O
best O
- I-GENE
corrected O
visual O
acuity I-GENE
of O
0 O
. O
08 I-GENE
( O
range O
hand O
motions I-GENE
/ I-GENE
0 O
. O
003 I-GENE
to O
0 O
. O
4 I-GENE
), O
improved O
by O
5 I-GENE
lines O
to O
a O
median O
final O
postoperative O
best O
- I-GENE
corrected O
visual O
acuity I-GENE
of O
0 O
. O
25 O
( O
range O
0 O
. O
025 I-GENE
- I-GENE
0 O
. O
5 I-GENE
) O
( O
P I-GENE
= O
0 O
. O
001 O
). O

Angina I-GENE
( O
Q I-GENE
) O
persistence I-GENE
showed O
marked O
associations O
with O
previous O
myocardial O
infarction O
, O
diagnosed O
angina O
, O
electrocardiogram O
ischemia O
, O
and O
subsequent O
major I-GENE
ischemic O
heart O
disease O
events O
from O
Q5 I-GENE
onward I-GENE
. O

Site I-GENE
- I-GENE
directed O
mutagenesis O
of O
CAR I-GENE
revealed O
that O
CAR I-GENE
residues O
Leu73 I-GENE
and O
Lys121 I-GENE
and O
/ I-GENE
or O
Lys123 I-GENE
are O
critical O
contact O
residues O
, O
with O
Tyr80 I-GENE
and O
Tyr83 I-GENE
being O
peripherally I-GENE
involved O
in O
the O
binding I-GENE
interaction O
with O
the O
Ad5 I-GENE
, O
Ad9 I-GENE
, O
Ad12 I-GENE
, O
and O
Ad41L I-GENE
fiber O
knobs I-GENE
. O

Transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
( O
TGF I-GENE
- I-GENE
beta I-GENE
) O
induced O
growth I-GENE
arrest O
of O
cells O
involves O
regulation O
of O
the O
activities O
of O
both O
D I-GENE
- I-GENE
and O
E I-GENE
- I-GENE
type I-GENE
cyclin I-GENE
kinase I-GENE
complexes I-GENE
thought O
to O
be O
mediated O
primarily O
by O
the O
regulation O
of O
p15 I-GENE
( O
Ink4b I-GENE
) O
and O
p27 I-GENE
( O
Kip1 I-GENE
) O
cyclin I-GENE
kinase I-GENE
inhibitors O
. O

These O
data O
indicate O
that O
the O
SmSmad2 I-GENE
responds I-GENE
to O
the O
TGF I-GENE
- I-GENE
beta I-GENE
signals O
by O
interaction O
with O
receptor I-GENE
I I-GENE
, O
which O
phosphorylates O
it O
, O
whereupon I-GENE
it O
translocates I-GENE
into O
the O
nucleus O
presumably O
to O
regulate O
target O
gene I-GENE
transcription I-GENE
and O
consequently I-GENE
elicit O
a O
specific I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
effect O
. O

We O
propose O
that O
TFOs I-GENE
represent O
a O
therapeutic O
potential O
to O
specifically O
diminish I-GENE
the O
expression O
of O
c I-GENE
- I-GENE
sis I-GENE
/ I-GENE
PDGF I-GENE
- I-GENE
B I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
in O
various O
pathologic O
settings I-GENE
where O
constitutive O
expression O
of O
this O
gene I-GENE
has O
been O
observed O
. O

The O
increased O
clearance O
observed O
in O
young O
infants O
is O
in O
contrast O
to O
other O
opioids I-GENE
. O

Peripheral I-GENE
metabolism O
of O
androgens I-GENE
takes I-GENE
place O
in O
various O
areas O
within O
the O
pilosebaceous I-GENE
unit I-GENE
, O
as O
indicated O
by O
local O
differences O
in O
the O
activities O
of O
aromatase I-GENE
, O
5alpha I-GENE
- I-GENE
reductase I-GENE
as O
well O
as O
of O
the O
presence O
of O
the O
androgen O
receptors I-GENE
. O

This O
unique O
location O
of O
cavernous I-GENE
malformation I-GENE
is O
associated I-GENE
with O
a O
risk O
of O
permanent O
loss O
of O
the O
vision O
. O

The O
JHRLSS I-GENE
has O
been O
used O
in O
prior O
studies O
to O
assess O
RLS I-GENE
severity O
, O
but O
has O
not O
previously O
been O
validated I-GENE
in O
relation O
to O
direct O
measures O
of O
the O
morbidity O
associated I-GENE
with O
RLS I-GENE
. O

Consistent O
effects O
on O
pVHL I-GENE
function O
were O
observed O
for O
all O
mutations O
within O
each O
subclass I-GENE
. O

Interestingly O
, O
the O
CYP71D20 I-GENE
- I-GENE
encoded I-GENE
enzyme I-GENE
activity O
was O
capable O
of O
converting I-GENE
both O
5 I-GENE
- I-GENE
epi I-GENE
- I-GENE
aristolochene I-GENE
and O
1 I-GENE
- I-GENE
deoxycapsidiol I-GENE
to O
capsidiol I-GENE
in O
vitro O
, O
consistent O
with O
the O
notion O
that O
this O
P450 I-GENE
enzyme I-GENE
catalyzes O
both O
hydroxylations I-GENE
of O
its O
hydrocarbon I-GENE
substrate I-GENE
. O

A I-GENE
new O
species O
of O
Euspondylus I-GENE
is O
described O
based O
on O
a O
female O
( O
taken O
within O
a O
bromeliad I-GENE
) O
from O
Cerro I-GENE
El I-GENE
Humo I-GENE
, O
Sucre I-GENE
, O
northeastern I-GENE
Venezuela I-GENE
. O

The O
most O
important O
finding O
, O
however O
, O
was O
that O
IMT I-GENE
values O
were O
related I-GENE
with O
24 O
h O
SBP I-GENE
or O
PP I-GENE
standard O
deviation O
( O
P I-GENE
< O
0 O
. O
001 O
), O
a O
measure O
of O
overall O
SBP I-GENE
or O
PP I-GENE
variability O
. O

In O
addition O
, O
severe O
vision O
loss O
can O
be O
seen O
with O
interferon I-GENE
alfa I-GENE
- I-GENE
2b I-GENE
- I-GENE
associated I-GENE
retinopathy I-GENE
. O

FLP I-GENE
and O
Cre I-GENE
recombinase I-GENE
function O
in O
Xenopus I-GENE
embryos O
. O

Keratoconjunctivitis I-GENE
sicca I-GENE
appears O
to O
be O
a O
common O
ocular O
complication O
and O
all O
children O
with O
JRA I-GENE
should O
be O
screened O
for O
it O
with O
a O
comprehensive I-GENE
battery O
of O
tests O
. O

Moreover O
, O
PTax I-GENE
expressed O
higher O
background O
activities O
than O
PTF I-GENE
, O
indicating O
that O
the O
sequence I-GENE
of O
the O
synthetic O
regulatory I-GENE
region O
can O
influence O
background O
levels O
. O

After O
allowing O
time O
for O
absorption O
, O
participants I-GENE
completed O
a O
bridge I-GENE
simulator I-GENE
task O
. O

The O
cleavage O
site I-GENE
between O
VPg I-GENE
and O
RNA I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
was O
predicted O
to O
be O
E445 I-GENE
- I-GENE
T446 I-GENE
based O
on O
the O
amino O
acid I-GENE
sequence I-GENE
analysis O
of O
the O
polyprotein I-GENE
from O
different O
sobemoviruses I-GENE
. O

Conformational I-GENE
changes O
of O
the O
ferric I-GENE
uptake O
regulation O
protein I-GENE
upon O
metal O
activation O
and O
DNA I-GENE
binding I-GENE
; O
first O
evidence O
of O
structural O
homologies O
with O
the O
diphtheria I-GENE
toxin I-GENE
repressor I-GENE
. O

At O
visit I-GENE
5 I-GENE
, O
the O
isokinetic I-GENE
test O
showed O
impaired O
muscle O
function O
recovery O
from O
23 O
% O
to O
32 O
%, O
while O
the O
manual I-GENE
test O
showed O
almost O
full I-GENE
recovery O
. O

Constitutive I-GENE
phosphorylation O
and O
nuclear I-GENE
localization O
of O
Smad3 I-GENE
are O
correlated O
with O
increased O
collagen I-GENE
gene I-GENE
transcription I-GENE
in O
activated I-GENE
hepatic I-GENE
stellate I-GENE
cells O
. O

Cholesteryl I-GENE
ester O
transfer I-GENE
protein I-GENE
and O
atherosclerosis O
in O
Japanese O
subjects O
: O
a O
study O
based O
on O
coronary O
angiography O
. O

And I-GENE
, O
most O
importantly I-GENE
, O
reconstitution I-GENE
of O
a O
consensus I-GENE
CRE O
, O
within O
the O
21 O
- I-GENE
bp O
enhancers I-GENE
increases O
binding I-GENE
of O
CREB I-GENE
/ I-GENE
ATF I-GENE
proteins I-GENE
but O
abrogates I-GENE
basal O
repression O
of O
LTR I-GENE
- I-GENE
directed O
transcription I-GENE
in O
vitro O
. O

Stable O
transfection O
of O
human I-GENE
CHOP I-GENE
cDNA I-GENE
into O
mammary O
carcinoma O
cells O
demonstrated O
that O
CHOP I-GENE
functioned O
not O
as O
a O
mediator I-GENE
of O
hGH I-GENE
- I-GENE
stimulated O
mitogenesis I-GENE
but O
rather O
enhanced O
the O
protection O
from O
apoptosis O
afforded I-GENE
by O
hGH I-GENE
in O
a O
p38 I-GENE
MAPK I-GENE
- I-GENE
dependent I-GENE
manner O
. O

The O
combination O
of O
ifosfamide I-GENE
, O
epirubicin I-GENE
and O
etoposide I-GENE
( O
IEV I-GENE
) O
is O
an O
effective O
salvage I-GENE
regimen O
for O
lymphoproliferative I-GENE
disease O
. O

Interestingly O
, O
the O
activity O
of O
IkappaB I-GENE
kinase I-GENE
( O
IKK I-GENE
- I-GENE
beta I-GENE
), O
which O
plays O
an O
essential O
role O
in O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
through O
IkappaB I-GENE
phosphorylation O
, O
was O
largely O
enhanced O
in O
paclitaxel I-GENE
- I-GENE
treated O
cells O
, O
detected O
as O
IkappaBalpha I-GENE
phosphorylation O
. O

The O
recessive O
hos1 I-GENE
mutation I-GENE
causes O
enhanced O
induction O
of O
the O
CBF I-GENE
transcription I-GENE
factors I-GENE
by O
low O
temperature O
as O
well O
as O
of O
their O
downstream O
cold O
- I-GENE
responsive I-GENE
genes I-GENE
. O

Apart I-GENE
from O
antimicrobial O
properties O
, O
recent O
data O
indicate O
that O
PMN I-GENE
also O
exert O
anti I-GENE
- I-GENE
inflammatory O
effects O
by O
stimulation O
and O
release O
of O
cytokine O
antagonists O
such O
as O
interleukin I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
antagonist O
( O
IL I-GENE
- I-GENE
1ra I-GENE
). O

Early O
indicators O
of O
the O
effect O
of O
a O
breast O
cancer O
screening O
program O
for O
low O
- I-GENE
income I-GENE
women O
. O

An O
association O
was O
demonstrated O
between O
the O
expression O
of O
aberrantly I-GENE
and O
/ I-GENE
or O
alternatively O
spliced O
mdm2 I-GENE
mRNAs I-GENE
and O
a O
lack O
of O
progesterone I-GENE
receptor I-GENE
. O

BACKGROUND O
: O
Dermoscopy I-GENE
is O
a O
noninvasive I-GENE
technique O
that O
increases O
the O
diagnostic O
accuracy O
of O
pigmented I-GENE
skin O
lesions O
, O
particularly O
improving I-GENE
the O
diagnosis O
of O
patients O
with O
cutaneous O
melanoma O
in O
situ O
( O
CMIS I-GENE
) O
and O
early I-GENE
invasive O
melanoma O
. O

Increased O
erythropoietin I-GENE
synthesis O
in O
patients O
with O
COLD I-GENE
or O
left O
heart O
failure O
is O
related I-GENE
to O
alterations O
in O
renal O
haemodynamics I-GENE
. O

The O
( O
two O
- I-GENE
motif I-GENE
) O
domain I-GENE
fold O
contains O
a O
pair O
of O
calcium O
binding I-GENE
sites I-GENE
very O
similar O
to O
those O
found O
in O
a O
two O
- I-GENE
domain I-GENE
prokaryotic I-GENE
betagamma I-GENE
- I-GENE
crystallin I-GENE
fold O
family I-GENE
member O
, O
Protein I-GENE
S I-GENE
. O

Twenty O
- I-GENE
five O
patients O
also O
received O
PET O
examinations O
during O
the O
staging I-GENE
procedures O
. O

In O
the O
last O
case O
, O
both O
hydroxychloroquine I-GENE
, O
carbamazepine I-GENE
and O
fluvoxamine I-GENE
had O
a O
common O
imputability I-GENE
which O
was O
plausible I-GENE
. O

In O
all O
of O
these O
cases O
, O
expression O
of O
the O
implicated O
genes I-GENE
was O
absent O
. O

A I-GENE
subset O
of O
patients O
( O
n O
= O
30 O
) O
underwent O
multichannel I-GENE
pressure O
flow O
studies O
, O
which O
demonstrated O
that O
transrectal I-GENE
HIFU I-GENE
reduces O
bladder O
outflow O
obstruction O
. O

Biochemical O
experiments O
have O
shown O
that O
CopG I-GENE
co O
- I-GENE
operatively I-GENE
associates O
to O
its O
target O
DNA I-GENE
at O
low O
protein I-GENE
: O
DNA I-GENE
ratios O
, O
completely O
protecting I-GENE
four O
helical O
turns I-GENE
on O
the O
same O
face O
of O
the O
double O
helix I-GENE
in O
both O
directions I-GENE
from O
the O
inverted O
repeat I-GENE
that O
constitutes O
the O
CopG I-GENE
primary O
target O
. O

The O
mechanism O
of O
ligand O
- I-GENE
activated I-GENE
estrogen I-GENE
receptor I-GENE
alpha I-GENE
( O
ERalpha I-GENE
)- I-GENE
dependent I-GENE
activation O
of O
gene I-GENE
expression O
through O
the O
SRE O
was O
determined O
by O
mutational O
analysis O
of O
the O
promoter I-GENE
, O
analysis O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
pathway O
activation O
by O
E2 I-GENE
, O
and O
transforming I-GENE
growth I-GENE
factor I-GENE
alpha I-GENE
( O
TGF I-GENE
- I-GENE
alpha I-GENE
) O
as O
a O
positive O
control O
. O

This O
study O
investigated O
whether O
boron I-GENE
would O
enhance O
the O
ability O
of O
17beta I-GENE
- I-GENE
estradiol O
( O
E2 I-GENE
) O
or O
parathyroid I-GENE
hormone I-GENE
( O
PTH I-GENE
) O
to O
improve O
bone O
quality O
in O
ovariectomized I-GENE
OVX I-GENE
rats O
. O

2001 I-GENE
. O

The O
Gap69C I-GENE
is O
a O
single O
- I-GENE
copy O
gene I-GENE
producing O
a O
major I-GENE
2 I-GENE
. O
1 I-GENE
- I-GENE
kb O
mRNA I-GENE
throughout O
development O
, O
but O
its O
amount O
is O
decreased O
in O
larvae O
. O

In O
the O
long O
term O
, O
questions O
still O
remain I-GENE
about O
whether O
pre I-GENE
- I-GENE
dialysis O
rHu I-GENE
EPO I-GENE
either O
speeds I-GENE
up O
or O
delays I-GENE
the O
onset O
of O
dialysis O
. O

The O
validity O
of O
the O
FPS I-GENE
- I-GENE
R I-GENE
was O
further O
supported O
by O
strong O
positive O
correlations O
with O
the O
VAS I-GENE
( O
r O
= O
0 O
. O
92 O
, O
N I-GENE
= O
45 O
) O
and O
the O
CAS I-GENE
( O
r O
= O
0 O
. O
84 O
, O
N I-GENE
= O
45 O
) O
in O
this O
clinical O
sample O
. O

The O
BFA I-GENE
System I-GENE
reads I-GENE
a O
text I-GENE
file I-GENE
with O
flows I-GENE
, O
measured O
with O
fluorescent O
microsphere I-GENE
technique O
, O
and O
constructs I-GENE
the O
lung O
anatomy I-GENE
with O
volumetric I-GENE
pixels I-GENE
showing O
the O
flows I-GENE
with O
a O
color O
schema I-GENE
. O

Therefore O
, O
to O
understand O
how O
ErbB1 I-GENE
/ I-GENE
ErbB2 I-GENE
signaling O
contributes O
to O
this O
process O
, O
we O
used O
the O
ErbB I-GENE
kinase I-GENE
inhibitor I-GENE
AG1478in I-GENE
ErbB2 I-GENE
- I-GENE
dependent I-GENE
BT I-GENE
- I-GENE
474 I-GENE
and O
SKBR I-GENE
- I-GENE
3 I-GENE
human I-GENE
breast O
cancer O
cells O
. O

Deletion O
analyses O
implicate I-GENE
the O
N I-GENE
- I-GENE
terminal I-GENE
110 I-GENE
amino O
acids O
of O
Grb14 I-GENE
and O
ankyrin I-GENE
repeats I-GENE
10 O
- I-GENE
19 O
of O
tankyrase I-GENE
2 I-GENE
in O
mediating O
this O
interaction O
. O

Hormonal I-GENE
regulation O
of O
multiple O
promoters I-GENE
of O
the O
rat I-GENE
mitochondrial I-GENE
glycerol I-GENE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
gene I-GENE
: O
identification O
of O
a O
complex I-GENE
hormone I-GENE
- I-GENE
response O
element I-GENE
in O
the O
ubiquitous O
promoter I-GENE
B I-GENE
. O

SAMPLE I-GENE
POPULATION I-GENE
: O
MCB I-GENE
from O
7 O
racing I-GENE
Greyhounds I-GENE
euthanatized I-GENE
for O
reasons I-GENE
unrelated O
to O
MCB I-GENE
abnormalities O
. O

Structural O
studies O
have O
shown O
that O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
)- I-GENE
restricted O
peptide I-GENE
- I-GENE
specific I-GENE
T I-GENE
cell O
receptor I-GENE
( O
TCR I-GENE
)- I-GENE
alpha I-GENE
/ I-GENE
betas I-GENE
make O
multiple O
contacts O
with O
the O
alpha1 I-GENE
and O
alpha2 I-GENE
helices O
of O
the O
MHC I-GENE
, O
but O
it O
is O
unclear O
which O
or O
how O
many O
of O
these O
interactions O
contribute O
to O
functional O
binding I-GENE
. O

Fans I-GENE
in O
tunnels I-GENE
and O
open O
windows I-GENE
at O
aboveground I-GENE
locations O
appeared O
to O
greatly O
reduce O
the O
likelihood O
of O
high O
PH3 I-GENE
concentrations O
in O
enclosed I-GENE
areas O
. O

In O
DNA I-GENE
strand O
exchange I-GENE
reactions O
using O
oligonucleotides O
, O
we O
found O
that O
Rec2 I-GENE
exhibited O
a O
pairing I-GENE
bias I-GENE
that O
is O
opposite O
that O
of O
RecA I-GENE
. O

A I-GENE
major I-GENE
mechanism O
by O
which O
estrogens I-GENE
prevent O
osteoporosis I-GENE
seems O
to O
be O
repression O
of O
transcription I-GENE
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
target O
genes I-GENE
, O
such O
as O
the O
osteoclast I-GENE
- I-GENE
activating I-GENE
cytokines O
interleukin I-GENE
- I-GENE
6 I-GENE
and O
interleukin I-GENE
- I-GENE
1 I-GENE
. O

Linear I-GENE
eight O
- I-GENE
or O
nine O
- I-GENE
residue O
D I-GENE
- I-GENE
peptides I-GENE
derived O
from O
the O
pocket O
- I-GENE
binding I-GENE
domain I-GENE
of O
the O
cyclic I-GENE
molecules I-GENE
also O
bind O
specifically O
. O

As O
expected O
, O
homologous O
loxP I-GENE
sequences I-GENE
efficiently O
underwent O
Cre I-GENE
- I-GENE
mediated O
recombination O
. O

Multistage I-GENE
models O
and O
the O
A I-GENE
- I-GENE
bomb I-GENE
survivor I-GENE
data O
: O
implications O
for O
carcinogenic I-GENE
mechanisms O
? O

The O
results O
indicate O
that O
a O
more O
differentiated O
diagnosis O
of O
the O
molar I-GENE
relationship O
will O
allow O
for O
a O
more O
causally I-GENE
directed O
correction O
of O
Class I-GENE
II I-GENE
molar I-GENE
relationship O
. O

It O
is O
surprising I-GENE
that O
dnaE173 I-GENE
, O
a O
potent O
mutator I-GENE
mutation I-GENE
specific I-GENE
for O
sequence I-GENE
substitution O
as O
well O
as O
single O
- I-GENE
base O
frameshift O
, O
did O
not O
enhance O
the O
frequency O
of O
the O
hot O
- I-GENE
spot I-GENE
frameshift O
mutation I-GENE
. O

Hypercalcemia I-GENE
associated I-GENE
with O
elevated O
serum I-GENE
PTH I-GENE
concentration O
indicating O
primary O
hyperparathyroidism I-GENE
was O
found O
in O
7 O
BC I-GENE
patients O
( O
7 O
%) O
and O
in O
none O
of O
healthy O
women O
or O
patients O
with O
thyroid I-GENE
cancer O
. O

[ O
figure I-GENE
: O
see I-GENE
text I-GENE
] O
The O
Stille I-GENE
coupling O
reaction O
has O
been O
performed O
in O
1 I-GENE
- I-GENE
butyl I-GENE
- I-GENE
3 I-GENE
- I-GENE
methylimidazolium I-GENE
tetrafluoroborate I-GENE
( O
BMIM I-GENE
BF4 I-GENE
), O
a O
room O
- I-GENE
temperature O
ionic O
liquid O
( O
RTIL I-GENE
). O

Examination O
of O
various O
promoter I-GENE
deletion O
mutants I-GENE
indicated O
that O
SF I-GENE
- I-GENE
1 I-GENE
acts O
through O
the O
proximal I-GENE
promoter I-GENE
region O
and O
upstream O
promoter I-GENE
sequences I-GENE
. O

ORF1 O
( O
1029 I-GENE
bp O
; O
EMBL I-GENE
databank I-GENE
, O
Accession I-GENE
No O
. O

Vector I-GENE
stocks I-GENE
containing O
envelope I-GENE
proteins I-GENE
from O
three O
different O
SIVmac I-GENE
clones O
, O
namely O
, O
SIVmac239 I-GENE
( O
T I-GENE
- I-GENE
lymphocyte I-GENE
tropic I-GENE
[ O
T I-GENE
- I-GENE
tropic I-GENE
]), I-GENE
SIVmac316 I-GENE
( O
macrophage I-GENE
tropic I-GENE
[ O
M I-GENE
- I-GENE
tropic I-GENE
]), I-GENE
and O
SIVmac1A11 I-GENE
( O
dualtropic I-GENE
), O
were O
tested O
. O

ISS I-GENE
and O
the O
acute O
physiology O
and O
chronic O
health O
evaluation O
( O
APACHE I-GENE
II I-GENE
) O
calculated O
on O
admission O
. O

Ga O
- I-GENE
67 O
and O
Tl O
- I-GENE
201 O
scintigraphy O
in O
extramedullary I-GENE
plasmacytoma I-GENE
: O
a O
case O
report O
. O

Finally O
, O
there O
are O
a O
growing O
number O
of O
arguments I-GENE
favouring I-GENE
the O
use O
of O
ACE I-GENE
inhibitors O
very O
early I-GENE
in O
patients O
with O
diabetes O
mellitus O
. O

This O
paper O
describes O
the O
results O
of O
an O
initial O
study O
on O
the O
application O
of O
linear O
solvation I-GENE
energy O
relationships O
( O
LSERs I-GENE
) O
to O
the O
prediction O
of O
internal O
standard O
compounds O
in O
reversed O
- I-GENE
phase O
liquid O
chromatographic O
( O
RPLC I-GENE
) O
method O
development O
. O

A I-GENE
38 O
- I-GENE
year O
- I-GENE
old O
woman O
with O
ulcerative I-GENE
colitis I-GENE
subsequently O
developed O
sarcoidosis I-GENE
. O

Blood O
from O
dams I-GENE
was O
collected O
prior O
to O
inoculation I-GENE
and O
at O
time O
of O
necropsy I-GENE
for O
measurement O
of O
IgM I-GENE
and O
IgG I-GENE
antibodies I-GENE
to O
M I-GENE
. O
pulmonis I-GENE
. O

She I-GENE
has O
since O
developed O
a O
positive O
anti I-GENE
- I-GENE
cardiolipin I-GENE
antibody I-GENE
but O
does O
not O
meet I-GENE
diagnostic O
criteria O
for O
systemic O
lupus O
erythematosis I-GENE
. O
CONCLUSION O
: O
The O
presence O
of O
known O
autoimmune I-GENE
disease O
in O
a O
woman O
with O
POF I-GENE
should O
not O
dissuade I-GENE
the O
clinician I-GENE
from O
evaluating O
for O
a O
potential O
genetic O
cause O
. O

The O
mutation I-GENE
experiments O
showed O
that O
the O
most O
critical O
sequence I-GENE
for O
the O
repression O
of O
PTH I-GENE
was O
5 I-GENE
'- O
GGGGGAGGGGAG I-GENE
- I-GENE
3 I-GENE
' O
(+ O
1 I-GENE
to O
+ I-GENE
12 O
) O
of O
PTHSR I-GENE
. O

Thus O
, O
while O
the O
folds I-GENE
of O
all O
Myb I-GENE
domains I-GENE
resemble I-GENE
each O
other O
closely O
, O
the O
function O
of O
each O
Myb I-GENE
domain I-GENE
depends O
on O
the O
amino O
acid I-GENE
residues O
that O
are O
located O
on O
the O
surface O
of O
each O
protein I-GENE
. O

A I-GENE
cDNA I-GENE
clone O
encoding O
C2H2 I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
, O
SCOF I-GENE
- I-GENE
1 I-GENE
, O
was O
isolated O
from O
soybean I-GENE
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
simplified I-GENE
methods O
for O
estimation O
of O
Technetium I-GENE
Tc O
99m O
( O
99mTc O
)- I-GENE
pentetate I-GENE
and O
orthoiodohippurate I-GENE
I I-GENE
131 O
( O
131I O
- I-GENE
OIH I-GENE
) O
plasma I-GENE
clearance O
in O
dogs O
and O
cats O
with O
1 I-GENE
and O
2 I-GENE
blood O
samples O
. O

Sevelamer I-GENE
hydrochloride I-GENE
( O
Renagel I-GENE
) O
is O
a O
nonabsorbed I-GENE
phosphate I-GENE
- I-GENE
binding I-GENE
polymer I-GENE
marketed I-GENE
for O
the O
treatment O
of O
hyperphosphatemia I-GENE
in O
adult O
patients O
receiving O
hemodialysis O
. O

Using O
a O
novel O
method O
combining I-GENE
chromatin O
immunoprecipitation O
and O
genomic O
array I-GENE
hybridization O
, O
we O
have O
identified O
a O
460 I-GENE
- I-GENE
kb O
CENP I-GENE
- I-GENE
A I-GENE
- I-GENE
binding I-GENE
DNA I-GENE
domain I-GENE
of O
a O
neocentromere I-GENE
derived O
from O
the O
20p12 I-GENE
region O
of O
an O
invdup I-GENE
( O
20p I-GENE
) O
human I-GENE
marker O
chromosome O
. O

Cases I-GENE
of O
lung O
cancer O
with O
intramedullary I-GENE
metastasis O
are O
rare O
, O
especially O
those O
diagnosed O
before O
death O
. O

Direct I-GENE
current O
polarography I-GENE
and O
differential O
pulse O
polarographic I-GENE
methods O
have O
been O
developed O
for O
the O
qualitative O
as O
well O
as O
quantitative O
analysis O
of O
vitamin O
B1 I-GENE
, O
B2 I-GENE
and O
B6 I-GENE
. O

Fluorimetric I-GENE
determination O
of O
methylmercury I-GENE
as O
an O
ion O
- I-GENE
association O
complex I-GENE
with O
rhodamine I-GENE
B I-GENE
in O
the O
presence O
of O
iodide I-GENE
. O

The O
corresponding O
genotype I-GENE
was O
determined O
with O
a O
restriction I-GENE
enzyme I-GENE
- I-GENE
based O
assay O
. O

Patients O
were O
divided O
into O
two O
group O
; O
Control O
group O
A I-GENE
in O
which O
a O
hot O
- I-GENE
water O
circulating O
system O
was O
used O
and O
group O
B I-GENE
in O
which O
a O
transtracheal I-GENE
heating I-GENE
and O
humidification I-GENE
system O
by O
ANAMED I-GENE
HUMITUBE I-GENE
was O
used O
, O
during O
gastric O
cancer O
operation O
. O

Mental I-GENE
rotation I-GENE
of O
paired I-GENE
figures I-GENE
engendered I-GENE
activation O
in O
the O
left O
superior O
parietal I-GENE
lobule I-GENE
and O
the O
right O
frontal O
medial O
gyrus O
. O

Here O
we O
demonstrate O
that O
the O
Ras I-GENE
- I-GENE
activated I-GENE
Raf I-GENE
- I-GENE
MEK I-GENE
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
( O
ERK I-GENE
) O
signaling O
pathway O
can O
specifically O
control O
the O
expression O
of O
individual O
integrin I-GENE
subunits I-GENE
in O
a O
variety O
of O
human I-GENE
and O
mouse I-GENE
cell O
lines O
. O

These O
TxRE I-GENE
contain O
cyclic I-GENE
AMP I-GENE
- I-GENE
responsive I-GENE
elements O
( O
CRE O
), O
but O
, O
remarkably O
, O
the O
" O
TGACGTCA I-GENE
" O
consensus I-GENE
is O
never O
strictly O
conserved O
in O
any O
viral I-GENE
strain O
( O
e O
. O
g O
., O
AGACGTCA I-GENE
, O
TGACGGCA I-GENE
, O
TGACCTCA I-GENE
). O

The O
hatcher I-GENE
incubators I-GENE
of O
both O
companies I-GENE
were O
also O
persistently I-GENE
contaminated O
with O
Salmonella I-GENE
livingstone I-GENE
and O
Salmonella I-GENE
thomasville I-GENE
in O
company I-GENE
A I-GENE
and O
with O
Salmonella I-GENE
senftenberg I-GENE
in O
company I-GENE
B I-GENE
. O

Binding O
of O
cell O
type I-GENE
- I-GENE
specific I-GENE
nuclear I-GENE
proteins I-GENE
to O
the O
5 I-GENE
'- O
flanking O
region O
of O
maize I-GENE
C4 I-GENE
phosphoenolpyruvate I-GENE
carboxylase I-GENE
gene I-GENE
confers O
its O
differential O
transcription I-GENE
in O
mesophyll I-GENE
cells O
. O

Susceptibility I-GENE
to O
ischemia O
- I-GENE
induced O
arrhythmias O
was O
lower O
in O
1 I-GENE
- I-GENE
week O
diabetics I-GENE
: O
only O
42 O
% O
of O
diabetic O
hearts O
exhibited O
ventricular O
tachycardia O
( O
VT O
) O
and O
16 O
% O
had O
short O
episodes O
of O
ventricular O
fibrillation O
( O
VF O
) O
as O
compared O
to O
VT O
100 O
% O
and O
VF O
70 I-GENE
% O
( O
including O
sustained O
VF O
36 O
%) O
in O
the O
non O
- I-GENE
diabetics I-GENE
( O
P I-GENE
< O
0 O
. O
05 O
). O

CONCLUSIONS O
: O
The O
methodology I-GENE
of O
LHR I-GENE
measurement O
significantly O
influences O
the O
clinical O
contribution O
of O
Tl O
- I-GENE
201 O
lung O
uptake O
evaluation O
. O

The O
authors O
made O
an O
analysis O
of O
social O
- I-GENE
economical I-GENE
conditions O
limiting O
the O
possibilities O
of O
rendering I-GENE
cardiosurgical I-GENE
care O
to O
children O
. O

METHODS O
: O
Experiments O
testing O
the O
new O
catheter O
and O
comparing O
it O
to O
the O
existing O
catheter O
included O
: O
( O
1 I-GENE
) O
measurement O
of O
the O
laser O
output O
beam O
sizes O
and O
divergences I-GENE
; O
( O
2 I-GENE
) O
evaluation O
of O
particulate O
matter O
generation O
during O
ablation O
of O
atherosclerotic I-GENE
tissue I-GENE
; O
( O
3 I-GENE
) O
measurement O
of O
ablation O
hole I-GENE
sizes O
and O
tissue I-GENE
penetration O
rates O
; O
( O
4 I-GENE
) O
histopathologic I-GENE
examination O
of O
laser O
- I-GENE
induced O
in O
vivo O
vessel O
wall O
injury O
. O

The O
reproductive O
effects O
of O
the O
administration O
of O
4 I-GENE
- I-GENE
chloro I-GENE
- I-GENE
2 I-GENE
- I-GENE
methylphenoxyacetic I-GENE
acid I-GENE
( O
MCPA I-GENE
) O
to O
rats O
were O
evaluated O
through O
two O
generations I-GENE
, O
from O
prior O
to O
mating I-GENE
, O
throughout O
mating I-GENE
, O
to O
gestation O
and O
lactation I-GENE
. O

Here O
we O
suggest O
that O
uvrA I-GENE
and O
the O
nucleotide I-GENE
excision O
repair I-GENE
pathway O
are O
involved O
in O
the O
repair I-GENE
of O
acid I-GENE
- I-GENE
induced O
DNA I-GENE
damage O
and O
are O
associated I-GENE
with O
successful O
adaptation O
of O
S I-GENE
. O
mutans I-GENE
to O
low O
pH O
. O

The O
improved O
CSF I-GENE
outflow O
conductance I-GENE
may O
increase O
the O
intracranial I-GENE
compliance O
and O
thereby O
dampen I-GENE
a O
pathological O
ICP I-GENE
waveform I-GENE
. O

These O
studies O
demonstrate O
that O
site I-GENE
- I-GENE
specific I-GENE
recognition I-GENE
of O
the O
bxd I-GENE
PRE I-GENE
by O
d O
( O
GA I-GENE
)( I-GENE
n O
) O
repeat I-GENE
binding I-GENE
activities O
mediates O
PcG I-GENE
- I-GENE
dependent I-GENE
silencing O
. O

The O
gonadotrope I-GENE
- I-GENE
specific I-GENE
and O
regulated O
expression O
of O
the O
GnRH I-GENE
receptor I-GENE
( O
GnRH I-GENE
- I-GENE
R I-GENE
) O
gene I-GENE
is O
dependent I-GENE
on O
multiple O
transcription I-GENE
factors I-GENE
that O
interact O
with O
the O
noncanonical I-GENE
GnRH I-GENE
- I-GENE
R I-GENE
activating I-GENE
sequence I-GENE
( O
GRAS I-GENE
), O
the O
activator I-GENE
protein I-GENE
- I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
element I-GENE
, O
and O
the O
steroidogenic I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
SF I-GENE
- I-GENE
1 I-GENE
) O
binding I-GENE
site I-GENE
. O

Before I-GENE
PO3 I-GENE
administration O
, O
more O
than O
half O
( O
57 O
. O
4 I-GENE
%) O
of O
the O
patients O
received O
only O
1 I-GENE
or O
2 I-GENE
antituberculous I-GENE
drugs O
( O
ethambutole I-GENE
and O
ethionamide I-GENE
or O
ethambutole I-GENE
and O
oprofloxacin I-GENE
). O

Using O
the O
presented O
categorical I-GENE
structure O
as O
domain I-GENE
model O
a O
prototype O
DSS I-GENE
for O
dipslide I-GENE
urine O
cultures O
has O
been O
developed O
. O

Conclusion I-GENE
: O
The O
Lp I-GENE
( O
a O
) O
levels O
in O
these O
children O
were O
the O
lower O
ever I-GENE
reported O
. O

Foxp1 I-GENE
and O
Foxp2 I-GENE
are O
expressed O
at O
high O
levels O
in O
the O
lung O
as O
early I-GENE
as O
E12 I-GENE
. O
5 I-GENE
of O
mouse I-GENE
development O
with O
Foxp2 I-GENE
expression O
restricted O
to O
the O
airway O
epithelium O
. O

Audiological I-GENE
findings O
in O
pregnancy O
. O

Children O
who O
developed O
lower O
respiratory O
tract O
infections O
or O
PCP I-GENE
had O
increased O
rates O
of O
decline O
of O
CD4 I-GENE
cell O
counts O
during O
the O
first O
6 I-GENE
months O
of O
life O
. O

A I-GENE
randomized O
mix I-GENE
of O
180 O
sections O
( O
10 O
samples O
x O
3 I-GENE
tissues O
x O
3 I-GENE
stains I-GENE
x O
2 I-GENE
) O
gave O
90 O
matched O
pairs O
. O

Sural I-GENE
nerve I-GENE
biopsy O
showed O
mild O
thickening I-GENE
of O
the O
perineurium I-GENE
, O
vascular I-GENE
alterations O
with O
inflammatory O
cell O
infiltration I-GENE
in O
the O
perineurium I-GENE
, O
and O
remarkable O
loss O
of O
large O
and O
small I-GENE
myelinated I-GENE
fibers O
. O

OBJECTIVES O
: O
The O
objective O
of O
this O
review O
was O
to O
assess O
the O
effects O
of O
prophylactic O
prostaglandin I-GENE
use O
in O
the O
third O
stage O
of O
labour O
. O

Testing I-GENE
was O
associated I-GENE
with O
a O
history O
of O
nonsexual I-GENE
risk O
behavior O
, O
increased O
knowledge O
of O
the O
hepatitis I-GENE
C I-GENE
virus I-GENE
, O
and O
healthcare I-GENE
provider I-GENE
communication I-GENE
. O

Cytomegalovirus I-GENE
, O
Chlamydia O
pneumoniae I-GENE
, O
and O
Helicobacter I-GENE
pylori I-GENE
IgG I-GENE
antibodies I-GENE
and O
restenosis I-GENE
after O
stent I-GENE
implantation O
: O
an O
angiographic O
and O
intravascular O
ultrasound O
study O
. O

A I-GENE
5 I-GENE
- I-GENE
month O
- I-GENE
old O
infant O
with O
persistent O
congenital O
stridor I-GENE
and O
acute O
respiratory O
distress O
is O
presented O
. O

OBJECTIVE O
: O
To O
determine O
whether O
RSTD I-GENE
predicts O
coronary O
anatomy I-GENE
during O
acute O
coronary O
occlusion O
. O

Even I-GENE
if O
the O
electrocardiographic I-GENE
signs O
are O
subdued I-GENE
, O
the O
underlying O
blockade O
of O
I I-GENE
( O
Kr I-GENE
) O
current O
may O
precipitate I-GENE
the O
occurrence O
of O
arrhythmia I-GENE
. O

Acetoin I-GENE
can O
be O
reused I-GENE
by O
the O
bacteria O
during O
stationary O
phase O
when O
other O
carbon O
sources O
have O
been O
depleted O
. O

Analysis O
of O
the O
promoter I-GENE
sequence I-GENE
revealed O
the O
presence O
of O
a O
major I-GENE
transcriptional O
start O
site I-GENE
, O
a O
canonical O
TATA I-GENE
box I-GENE
and O
putative O
cis O
regulatory I-GENE
elements O
for O
pituitary I-GENE
specific I-GENE
expression O
as O
well O
as O
an O
E I-GENE
- I-GENE
responsive I-GENE
element I-GENE
. O

IL I-GENE
- I-GENE
1beta I-GENE
was O
significantly O
higher O
in O
endometrioma I-GENE
than O
in O
lesions O
of O
other O
localizations I-GENE
. O

An O
economic I-GENE
analysis O
using O
West I-GENE
of O
Scotland I-GENE
Coronary O
Prevention O
Study O
( O
WOSCOPS I-GENE
) O
findings O
indicates O
that O
statin I-GENE
treatment O
would O
have O
prevented O
318 I-GENE
events O
per O
10 O
, O
000 O
patients O
in O
a O
population O
similar O
to O
that O
in O
WOSCOPS I-GENE
( O
average O
1 I-GENE
. O
5 I-GENE
% O
annual O
risk O
of O
a O
cardiovascular O
event O
) O
at O
a O
discounted I-GENE
cost O
per O
life O
- I-GENE
year O
gained I-GENE
of O
20 O
, O
375 I-GENE
pounds I-GENE
($ I-GENE
31 O
, O
818 I-GENE
). O

Hydrogels I-GENE
for O
tissue I-GENE
engineering I-GENE
. O

No O
mutation I-GENE
of O
the O
NRL I-GENE
gene I-GENE
was O
found O
in O
any O
of O
the O
two O
families O
. O

However O
, O
most O
produced O
significant O
alteration O
of O
small I-GENE
intestinal O
permeability I-GENE
. O

Our O
results O
show O
that O
CVN I-GENE
specifically O
recognizes O
with O
nanomolar I-GENE
affinity O
Man I-GENE
( O
9 O
) O
GlcNAc I-GENE
( O
2 I-GENE
) O
and O
the O
D1D3 I-GENE
isomer I-GENE
of O
Man I-GENE
( O
8 O
) O
GlcNAc I-GENE
( O
2 I-GENE
). O

Saccharomyces I-GENE
cerevisiae I-GENE
activates O
a O
regulatory I-GENE
network O
called O
" O
general O
control O
" O
that O
provides O
the O
cell O
with O
sufficient O
amounts O
of O
protein I-GENE
precursors I-GENE
during O
amino O
acid I-GENE
starvation O
. O

In O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
entry O
into O
mitosis O
requires O
activation O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
Cdc28 I-GENE
in O
its O
cyclin I-GENE
B I-GENE
( O
Clb I-GENE
)- I-GENE
associated I-GENE
form O
. O

Data O
from O
in O
vitro O
splicing O
assays O
, O
UV O
crosslinking I-GENE
and O
RNA I-GENE
- I-GENE
binding I-GENE
competition O
experiments O
indicates O
a O
strong O
correlation O
between O
the O
binding I-GENE
affinities O
of O
PSI I-GENE
for O
the O
SELEX I-GENE
sequences I-GENE
and O
their O
ability O
to O
modulate O
splicing O
of O
P I-GENE
element I-GENE
IVS3 I-GENE
in O
vitro O
. O

The O
sensitivity O
of O
human I-GENE
neuroblastoma O
cells O
SK I-GENE
- I-GENE
N I-GENE
- I-GENE
SH I-GENE
to O
undergo O
apoptosis O
induced O
by O
thapsigargin I-GENE
was O
examined O
. O

A I-GENE
., O
Slatkin I-GENE
, O
D I-GENE
. O

Multiparous I-GENE
women O
presented O
higher O
BMI O
( O
P I-GENE
= O
0 O
. O
01 O
) O
and O
PBF I-GENE
( O
P I-GENE
= O
0 O
. O
03 O
) O
compared O
with O
primi I-GENE
- I-GENE
and O
nulliparous I-GENE
groups O
. O

CONCLUSIONS O
AND O
CLINICAL I-GENE
RELEVANCE I-GENE
: O
Increased O
cortical O
thickness O
and O
geometric I-GENE
properties O
of O
left O
MCB I-GENE
- I-GENE
IV I-GENE
and O
- I-GENE
V I-GENE
of O
Greyhounds I-GENE
, O
together O
with O
altered O
turnover O
and O
orientation O
of O
osteons I-GENE
in O
the O
dorsal O
quadrants I-GENE
of O
left O
MCB I-GENE
, O
are O
site I-GENE
- I-GENE
specific I-GENE
adaptive O
responses O
associated I-GENE
with O
asymmetric O
cyclic I-GENE
loading O
as O
a O
result O
of O
racing I-GENE
on O
circular O
tracks I-GENE
. O

To O
examine O
transcriptional O
regulation O
of O
the O
rat I-GENE
eIF4E I-GENE
gene I-GENE
, O
2 I-GENE
. O
1 I-GENE
kB I-GENE
of O
the O
rat I-GENE
eIF4E I-GENE
promoter I-GENE
region O
was O
cloned O
and O
the O
contribution O
of O
specific I-GENE
elements O
in O
regulating O
transcription I-GENE
was O
determined O
in O
primary O
cultures O
of O
rat I-GENE
cardiocytes I-GENE
and O
in O
a O
murine I-GENE
C I-GENE
( O
2 I-GENE
) O
C I-GENE
( O
12 O
) O
myoblast I-GENE
cell O
line O
. O

The O
prevalence O
of O
tobacco I-GENE
dependence O
diagnosed O
according O
to O
the O
ICD I-GENE
- I-GENE
10 O
criteria O
was O
higher O
in O
alcohol O
- I-GENE
dependent I-GENE
individuals O
( O
58 O
. O
1 I-GENE
%) O
than O
in O
nondrinkers I-GENE
or O
social O
drinkers I-GENE
( O
12 O
. O
8 O
%). O

Management I-GENE
of O
postvitrectomy I-GENE
diabetic O
vitreous O
hemorrhage O
with O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
and O
volume O
homeostatic I-GENE
fluid O
- I-GENE
fluid O
exchanger I-GENE
. O

Transactivation I-GENE
of O
oIFNtau I-GENE
enhancer I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
was O
primarily O
regulated O
by O
three O
regions O
containing O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
GATA I-GENE
like I-GENE
sequence I-GENE
and O
site I-GENE
( O
s O
) O
unidentified O
. O

SELECTION I-GENE
CRITERIA I-GENE
: O
Randomised I-GENE
controlled O
trials O
of O
cabergoline I-GENE
versus O
placebo O
in O
patients O
with O
a O
clinical O
diagnosis O
of O
idiopathic O
Parkinson O
' O
s O
disease O
and O
long O
- I-GENE
term O
complications O
of O
levodopa I-GENE
therapy O
. O

0 O
%) O
and O
IL I-GENE
- I-GENE
12 O
( O
42 O
. O
6 I-GENE
% O
vs O
. O

Copyright O
2000 O
John I-GENE
Wiley I-GENE
& O
Sons I-GENE
, O
Ltd I-GENE
. O

Here O
we O
demonstrate O
that O
native O
MRCK I-GENE
exists O
in O
high O
- I-GENE
molecular O
- I-GENE
weight O
complexes I-GENE
. O

METHODS O
: O
This O
retrospective O
review O
comprised O
2711 I-GENE
eyes O
that O
had O
LASIK I-GENE
between O
September I-GENE
1996 O
and O
September I-GENE
1999 I-GENE
. O

Sixty I-GENE
- I-GENE
one O
cases O
of O
cholera I-GENE
, O
all O
caused O
by O
V I-GENE
. O
cholerae I-GENE
O1 I-GENE
, O
were O
reported O
. O

This O
could O
lead O
to O
subsequent O
outbreaks I-GENE
if O
Babesia I-GENE
carrier I-GENE
animals O
were O
to O
be O
introduced O
into O
the O
herd O
. O

Instead O
, O
TRPS1 I-GENE
potently I-GENE
and O
specifically O
represses O
transcriptional O
activation O
mediated O
by O
other O
GATA I-GENE
factors I-GENE
. O

Eliminating I-GENE
any O
subset O
of O
ASCUS I-GENE
reduces O
the O
ASCUS I-GENE
/ I-GENE
SIL I-GENE
ratio O
but O
also O
significantly O
diminishes I-GENE
the O
sensitivity O
of O
the O
Papanicolaou I-GENE
test O
. O

In O
order O
to O
overcome O
the O
false O
positive O
readings I-GENE
that O
are O
possible O
in O
sphincter I-GENE
manometry I-GENE
, O
we O
proposed O
to O
use O
secretin I-GENE
stimulated O
endoscopic I-GENE
ultrasound O
( O
SSEUS I-GENE
) O
to O
measure O
pancreatic O
ductal I-GENE
response O
as O
an O
adjunctive I-GENE
method O
to O
aid O
and O
supplement I-GENE
the O
diagnosis O
. O

Endovascular I-GENE
aneurysm I-GENE
repair I-GENE
with O
the O
AneuRx I-GENE
stent I-GENE
- I-GENE
graft O
is O
safe O
, O
but O
is O
it O
effective O
? O

The O
difference O
of O
hardness I-GENE
over O
time O
of O
composite O
specimens O
was O
measured O
using O
Knoop I-GENE
hardness I-GENE
measurements O
taken O
at O
the O
top O
and O
bottom I-GENE
surfaces I-GENE
of O
resin O
specimens O
made O
in O
a O
Teflon I-GENE
mold I-GENE
the O
same O
dimensions O
as O
the O
cavity O
prepared O
in O
dentin O
. O

Implications I-GENE
in O
biomonitoring I-GENE
of O
the O
observed O
accumulation O
patterns O
, O
especially O
in O
the O
different O
tissues O
of O
Posidonia I-GENE
oceanica I-GENE
, O
are O
discussed O
. O

Based O
on O
mutational O
data O
and O
possible O
mRNA I-GENE
structure O
, O
we O
hypothesized I-GENE
about O
the O
effect O
of O
mRNA I-GENE
structure O
on O
translation I-GENE
of O
the O
two O
major I-GENE
C I-GENE
/ I-GENE
EBPepsilon I-GENE
isoforms I-GENE
: O
p32 I-GENE
and O
p30 I-GENE
. O

Retinoids I-GENE
participate O
in O
the O
onset O
of O
differentiation O
, O
apoptosis O
and O
the O
inhibition O
of O
growth I-GENE
in O
a O
wide O
variety O
of O
normal O
and O
cancerous I-GENE
cells O
. O

We O
conclude O
that O
RPMS I-GENE
acts O
as O
a O
negative O
regulator I-GENE
of O
EBNA2 I-GENE
and O
Notch I-GENE
activity O
through O
its O
interactions O
with O
the O
CBF1 I-GENE
- I-GENE
associated I-GENE
corepressor I-GENE
complex I-GENE
. O

Isolated I-GENE
Systolic I-GENE
Hypertension I-GENE
: O
An O
Update I-GENE
. O

Transfection O
of O
EGFP I-GENE
- I-GENE
tagged O
DENTT I-GENE
NLS O
deletion O
constructs I-GENE
lacking O
the O
bipartite O
NLS O
- I-GENE
1 I-GENE
were O
excluded O
from O
the O
nucleolus I-GENE
. O

VE O
- I-GENE
DEF I-GENE
animals O
had O
significantly O
higher O
( O
p O
< O
0 O
. O
05 O
) O
levels O
of O
myocardial O
lipid O
peroxidation O
and O
lower O
( O
p O
< O
0 O
. O
05 O
) O
protein I-GENE
thiols I-GENE
following O
I I-GENE
- I-GENE
R I-GENE
compared O
to O
the O
CON I-GENE
animals O
. O

The O
position O
of O
the O
analyst I-GENE
as O
expert I-GENE
: O
yesterday I-GENE
and O
today I-GENE
. O

Furthermore O
, O
we O
showed O
that O
ERSF I-GENE
including O
NF I-GENE
- I-GENE
Y I-GENE
and O
ATF6alpha I-GENE
and O
/ I-GENE
or O
beta I-GENE
and O
capable O
of O
binding I-GENE
to O
ERSE I-GENE
is O
indeed O
formed O
when O
the O
cellular O
UPR I-GENE
is O
activated I-GENE
. O

We O
performed O
the O
present O
study O
to O
clarify O
the O
relationship O
between O
the O
DOX I-GENE
binding I-GENE
ability O
(% I-GENE
DB I-GENE
) O
and O
the O
histologic O
response O
, O
rate O
of O
decrease O
in O
tumor I-GENE
volume O
of O
malignant O
soft O
tissue I-GENE
tumors O
after O
preoperative O
chemotherapy O
and O
prognosis O
. O

We O
have O
also O
isolated O
and O
analyzed O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
pea I-GENE
33RNP I-GENE
gene I-GENE
. O

We O
have O
previously O
shown O
that O
the O
adenoviral I-GENE
12S I-GENE
E1A I-GENE
protein I-GENE
modulates I-GENE
the O
phosphorylation O
status O
of O
p130 I-GENE
and O
p107 I-GENE
without O
apparent O
changes O
in O
the O
cell O
cycle O
dependent I-GENE
phosphorylation O
of O
the O
retinoblastoma I-GENE
protein I-GENE
. O

Baseline I-GENE
MBF I-GENE
in O
females O
was O
significantly O
( O
P I-GENE
< O
0 O
. O
001 O
) O
higher O
than O
in O
males O
. O

Only O
nine O
patients O
were O
offered O
surgery O
( O
six O
were O
resected I-GENE
and O
three O
were O
found O
inoperable I-GENE
). O

The O
deubiquitinating I-GENE
enzyme I-GENE
DUB I-GENE
- I-GENE
2 I-GENE
is O
induced O
in O
response O
to O
IL I-GENE
- I-GENE
2 I-GENE
but O
as O
yet O
its O
function O
has O
not O
been O
determined O
. O

A I-GENE
split I-GENE
motor O
domain I-GENE
in O
a O
cytoplasmic I-GENE
dynein I-GENE
. O

Immunological I-GENE
and O
biochemical O
characterization O
of O
streptococcal I-GENE
pyrogenic I-GENE
exotoxins I-GENE
I I-GENE
and O
J O
( O
SPE I-GENE
- I-GENE
I I-GENE
and O
SPE I-GENE
- I-GENE
J O
) O
from O
Streptococcus I-GENE
pyogenes I-GENE
. O

Five O
modalities O
of O
nonpharmacologic I-GENE
approaches O
are O
recommended O
at O
present O
for O
lifestyle I-GENE
modification O
and O
control O
of O
arterial O
blood O
pressure O
elevation O
: O
1 I-GENE
) O
weight O
reduction O
to O
ideal I-GENE
body O
weight O
, O
since O
it O
reduces O
risk O
of O
hypertension O
as O
well O
as O
overall O
cardiovascular O
morbidity O
and O
mortality O
; O
2 I-GENE
) O
dietary O
sodium O
restriction I-GENE
to O
less O
than O
2 I-GENE
g O
a O
day O
, O
without O
assurance I-GENE
that O
it O
will O
normalize I-GENE
arterial O
pressure O
although O
it O
may O
help O
reduce O
dosage O
and O
numbers O
of O
prescribed I-GENE
antihypertensive O
drugs O
; O
3 I-GENE
) O
moderation I-GENE
of O
alcohol O
consumption O
to O
less O
than O
1 I-GENE
ounce I-GENE
a O
day O
; O
4 I-GENE
) O
a O
regular O
isotonic I-GENE
exercise O
program O
; O
and O
5 I-GENE
) O
cessation O
of O
tobacco I-GENE
consumption O
. O

Descriptions I-GENE
of O
this O
locus I-GENE
would O
allow O
comparison O
with O
functionally O
relevant O
molecular O
genetic O
features O
of O
other O
species O
' O
homologous O
loci I-GENE
including O
the O
single O
- I-GENE
copy O
equid I-GENE
LH I-GENE
/ I-GENE
CGbeta I-GENE
gene I-GENE
and O
the O
primate O
LHbeta I-GENE
- I-GENE
CGbeta I-GENE
gene I-GENE
cluster I-GENE
locus I-GENE
. O

METHODS O
: O
One O
hundred O
fourteen I-GENE
consecutive O
patients O
( O
mean O
age O
61 O
years O
) O
with O
focal I-GENE
pancreatic O
masses O
, O
detected O
on O
CT I-GENE
, O
underwent O
EUS I-GENE
- I-GENE
FNA I-GENE
by O
using O
a O
linear O
- I-GENE
array I-GENE
echoendoscope I-GENE
and O
22 O
- I-GENE
gauge I-GENE
needles I-GENE
. O

The O
effects O
of O
chlordiazepoxide I-GENE
( O
2 I-GENE
. O
5 I-GENE
- I-GENE
15 O
. O
0mg I-GENE
/ I-GENE
kg O
), O
a O
full I-GENE
benzodiazepine I-GENE
receptor I-GENE
agonist O
, O
and O
bretazenil I-GENE
( O
5 I-GENE
. O
0 O
- I-GENE
30 O
. O
0mg I-GENE
/ I-GENE
kg O
), O
a O
partial O
benzodiazepine I-GENE
receptor I-GENE
agonist O
, O
were O
examined O
in O
the O
murine I-GENE
elevated O
plus O
- I-GENE
maze I-GENE
paradigm I-GENE
. O

Acute O
effects O
of O
LI I-GENE
160 I-GENE
( O
extract O
of O
Hypericum I-GENE
perforatum I-GENE
, O
St I-GENE
John I-GENE
' O
s O
wort I-GENE
) O
and O
two O
of O
its O
constituents I-GENE
on O
neuroendocrine I-GENE
responses O
in O
the O
rat I-GENE
. O

Guidelines I-GENE
for O
performing I-GENE
a O
routine O
spiral I-GENE
assay O
are O
presented O
, O
and O
alternative O
test O
methods O
intended I-GENE
to O
overcome O
a O
variety O
of O
technical I-GENE
difficulties I-GENE
( O
such O
as O
restricted O
sample O
availability O
, O
sample O
viscosity O
or O
volatility I-GENE
, O
etc O
.) O
are O
recommended O
. O

An O
additional O
9 O
patients O
achieved O
normal O
levels O
with O
adjunctive I-GENE
drug O
therapy O
. O

Anti I-GENE
- I-GENE
nucleolin I-GENE
mAb I-GENE
was O
used O
to O
confirm O
the O
antigenic I-GENE
properties O
of O
this O
p95 I-GENE
component O
. O

Eliminating I-GENE
any O
subset O
of O
ASCUS I-GENE
reduces O
the O
ASCUS I-GENE
/ I-GENE
SIL I-GENE
ratio O
but O
also O
significantly O
diminishes I-GENE
the O
sensitivity O
of O
the O
Papanicolaou I-GENE
test O
. O

Prrp I-GENE
can O
also O
associate O
with O
the O
EVH1 I-GENE
domain I-GENE
of O
Mena I-GENE
, O
another O
microfilament I-GENE
- I-GENE
associated I-GENE
protein I-GENE
. O

Experience I-GENE
with O
xylene O
- I-GENE
free O
sections O
since O
1995 O
at O
the O
Vrinnevi I-GENE
Hospital I-GENE
is O
favorable I-GENE
. O

Acquired I-GENE
antithrombin I-GENE
deficiency O
in O
sepsis O
. O

SIP1 I-GENE
( O
Smad I-GENE
interacting I-GENE
protein I-GENE
1 I-GENE
) O
and O
deltaEF1 I-GENE
( O
delta I-GENE
- I-GENE
crystallin I-GENE
enhancer I-GENE
binding I-GENE
factor I-GENE
) O
are O
structurally O
similar O
transcriptional O
repressors I-GENE
. O

SERS I-GENE
spectra O
were O
obtained O
by O
vacuum I-GENE
evaporation I-GENE
and O
casting I-GENE
of O
p O
- I-GENE
NTP I-GENE
onto O
silver O
island O
films O
, O
and O
also O
from O
colloidal I-GENE
silver O
solutions O
. O

The O
moduli I-GENE
of O
elasticity I-GENE
of O
the O
gray O
and O
white O
matter O
were O
3 I-GENE
. O
4 I-GENE
+/- O
1 I-GENE
. O
4 I-GENE
kPa I-GENE
( O
mean O
+/- O
standard O
deviation O
) O
and O
3 I-GENE
. O
4 I-GENE
+/- O
0 O
. O
9 O
kPa I-GENE
in O
the O
axial O
section O
, O
3 I-GENE
+/- O
0 O
. O
3 I-GENE
kPa I-GENE
and O
3 I-GENE
. O
5 I-GENE
+/- O
0 O
. O
5 I-GENE
kPa I-GENE
in O
the O
frontal O
section O
, O
and O
3 I-GENE
. O
5 I-GENE
+/- O
0 O
. O
9 O
kPa I-GENE
and O
2 I-GENE
. O
8 O
+/- O
0 O
. O
4 I-GENE
kPa I-GENE
in O
the O
sagittal I-GENE
section O
, O
respectively O
. O

[ O
Clinical O
and O
epidemiological O
characteristics O
of O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
in O
women O
] O
BACKGROUND O
: O
Squamous I-GENE
cell O
carcinoma O
( O
SCC I-GENE
) O
of O
the O
oral O
cavity O
occurs O
mainly O
in O
the O
male O
population O
. O

The O
core I-GENE
promoter I-GENE
of O
human I-GENE
thioredoxin I-GENE
reductase I-GENE
1 I-GENE
: O
cloning O
, O
transcriptional O
activity O
, O
and O
Oct I-GENE
- I-GENE
1 I-GENE
, O
Sp1 I-GENE
, O
and O
Sp3 I-GENE
binding I-GENE
reveal O
a O
housekeeping O
- I-GENE
type I-GENE
promoter I-GENE
for O
the O
AU I-GENE
- I-GENE
rich O
element I-GENE
- I-GENE
regulated O
gene I-GENE
. O

Phase O
II I-GENE
trial O
of O
the O
anti I-GENE
- I-GENE
G I-GENE
( O
D2 I-GENE
) O
monoclonal I-GENE
antibody I-GENE
3F8 I-GENE
and O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
for O
neuroblastoma O
. O

A I-GENE
log O
- I-GENE
linear O
dose O
- I-GENE
response O
was O
obtained O
for O
the O
average O
increase O
in O
FEV1 O
up O
to O
6 I-GENE
h O
( O
AUC0 I-GENE
- I-GENE
6 I-GENE
h O
) O
and O
peak O
FEV1 O
across O
the O
dose O
range O
administered O
by O
Respimat I-GENE
. O

Plasma I-GENE
DHE I-GENE
concentration O
rose O
promptly I-GENE
above O
5 I-GENE
ng O
/ I-GENE
ml O
after O
the O
application O
of O
the O
PSA I-GENE
tape I-GENE
onto O
the O
damaged O
skin O
in O
hairless I-GENE
rat I-GENE
. O

A I-GENE
complete O
drug O
history O
was O
compiled I-GENE
, O
specifying I-GENE
the O
amount O
and O
duration O
of O
VGB I-GENE
medication O
. O

Epithelial I-GENE
cytotoxicity O
of O
combined O
antibiotics O
was O
additive O
, O
with O
no O
evidence O
of O
competition O
or O
synergism I-GENE
. O

In O
Cd O
- I-GENE
spiked I-GENE
OECD I-GENE
soil I-GENE
, O
internal O
Cd O
levels O
were O
linearly I-GENE
related I-GENE
to O
external O
Cd O
concentrations O
, O
whereas O
the O
springtails I-GENE
maintained O
fixed O
internal O
levels O
of O
Cu I-GENE
and O
Zn I-GENE
regardless O
of O
spiked I-GENE
concentrations O
. O

Interestingly O
, O
the O
similarities O
with O
the O
endophilin I-GENE
proteins I-GENE
cover I-GENE
the O
entire O
sequence I-GENE
of O
the O
SH3GLB I-GENE
family I-GENE
, O
suggesting O
a O
common O
fold O
and O
presumably O
a O
common O
mode O
of O
action O
. O

Reovirus I-GENE
mRNAs I-GENE
are O
efficiently O
translated O
within O
host O
cells O
despite O
the O
absence O
of O
3 I-GENE
' O
polyadenylated O
tails O
. O

Grippers I-GENE
with O
integrated O
piezoresistive I-GENE
force O
sensors I-GENE
and O
with O
attached O
strain O
gauges I-GENE
have O
been O
reported O
. O

Both O
Z I-GENE
and O
R I-GENE
expression O
resulted O
in O
PML I-GENE
dispersion O
in O
EBV I-GENE
- I-GENE
positive O
cells O
. O

The O
small I-GENE
copepod I-GENE
Pseudonychocamptus I-GENE
proximus I-GENE
progressively I-GENE
replaced O
the O
large O
Tisbe I-GENE
furcata I-GENE
in O
sand I-GENE
filters I-GENE
during O
the O
fall O
of O
1995 O
and O
was O
responsible O
for O
the O
large O
increase O
in O
meiofaunal I-GENE
biomass I-GENE
observed O
after O
spring I-GENE
1996 O
. O

Evidence O
- I-GENE
based O
care O
: O
a O
new O
formula O
for O
an O
old O
problem O
? O

Nrf2 I-GENE
regulates O
expression O
of O
genes I-GENE
encoding O
enzymes O
with O
antioxidant O
( O
e O
. O
g O
. O
heme O
oxygenase I-GENE
- I-GENE
1 I-GENE
( O
HO I-GENE
- I-GENE
1 I-GENE
)) O
or O
xenobiotic I-GENE
detoxification I-GENE
( O
e O
. O
g O
. O

Workload I-GENE
, O
UAPs I-GENE
, O
and O
you I-GENE
. O

RESULTS O
: O
At O
latest I-GENE
examination O
, O
mean O
UPDRS I-GENE
II I-GENE
and O
III I-GENE
scores O
had O
improved O
by O
30 O
% O
( O
on O
stimulation O
, O
off O
therapy O
) O
with O
mean O
50 O
% O
reduction O
in O
daily O
off O
time O
. O

Perfusion I-GENE
technique O
for O
perfusion O
- I-GENE
assisted I-GENE
direct O
coronary O
artery O
bypass O
( O
PADCAB I-GENE
). O

Copyright O
2001 I-GENE
Academic O
Press O
. O

The O
amount O
of O
drained I-GENE
effusion I-GENE
was O
measured O
, O
and O
fluid O
was O
sent I-GENE
for O
diagnostic O
assessment O
. O

